

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024162 A1

(51) International Patent Classification⁷: **A61K 31/517**,
C07D 239/95, 401/12, 403/04, A61P 3/06

[DE/DE]; Wingertstrasse 24, 69207 Sandhausen (DE).
HERMANN, Kristina [DE/DE]; Viernheimer Strasse 32,
68623 Lampertheim (DE).

(21) International Application Number:

PCT/EP2003/007067

(74) Agents: **KRAUSS, Jan, B. et al.**; Boehmert & Boehmert,
Pettenkoferstrasse 20-22, 80336 Munich (DE).

(22) International Filing Date: 2 July 2003 (02.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02020255.2 10 September 2002 (10.09.2002) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **LION
BIOSCIENCE AG** [DE/DE]; Waldhofer Strasse 98,
69123 Heidelberg (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DEUSCHLE, Ul-
rich** [DE/DE]; Wundtstrasse 9/20, 69123 Heidelberg (DE).
LOEBBERT, Ralph [DE/DE]; Hildastrasse 21, 69115
Heidelberg (DE). **BLUME, Beatrix** [DE/DE]; Hein-
rich-Heine-Strasse 20, 69221 Dossenheim (DE). **KOEGL,
Manfred** [DE/DE]; Hauptstrasse 131/4, 69214 Eppelheim
(DE). **KREMOSER, Claus** [DE/DE]; Mozartstrasse 29,
69121 Heidelberg (DE). **KOBER, Ingo** [DE/DE]; Am
Grossen Wald 30, 69251 Gaiberg (DE). **BAUER, Ulrike**


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: 2-AMINO-4-QUINAZOLINONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS



(1)

(57) Abstract: The present invention relates to 2-amino-4-oxo-quinazo-
lines according to the general formula (1), which bind to the LXR recep-
tors and act as agonists and antagonists of the LXR receptors. The inven-
tion further relates to the treatment of diseases and/or conditions through
binding of said nuclear receptor by said compounds and the production
of medicaments using said compounds. In particular the compounds are
useful in the treatment of hypercholesterolemia, obesity or other diseases
associated with elevated lipoprotein (LDL) levels.

WO 2004/024162 A1

2-AMINO-4-QUINAZOLINONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS

The present invention relates to compounds according to the general formula (1), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.

BACKGROUND OF THE INVENTION

Multicellular organisms are dependent on advanced mechanisms of information transfer between cells and body compartments. The information that is transmitted can be highly complex and can result in the alteration of genetic programs involved in cellular differentiation, proliferation, or reproduction. The signals, or hormones, are often simple molecules, such as peptides, fatty acid, or cholesterol derivatives.

Many of these signals produce their effects by ultimately changing the transcription of specific genes. One well-studied group of proteins that mediate a cell's response to a variety of signals is the family of transcription factors known as nuclear receptors, hereinafter referred to often as "NR". Members of this group include receptors for steroid hormones, vitamin D, ecdysone, cis and trans retinoic acid, thyroid hormone, bile acids, cholesterol-derivatives, fatty acids (and other peroxisomal proliferators), as well as so-called orphan receptors, proteins that are structurally similar to other members of this group, but for which no ligands are known (Escriva, H. et al., Ligand binding was acquired during evolution of nuclear receptors, PNAS, 94, 6803 – 6808, 1997). Orphan receptors may be indicative of unknown signaling pathways in the cell or may be nuclear receptors that function without ligand activation. The activation of transcription by some of these orphan receptors may occur in the absence of an exogenous ligand and/or through signal transduction pathways originating from the cell surface (Mangelsdorf, D. J. et al., The nuclear receptor superfamily: the second decade, Cell 83, 835-839, 1995).

In general, three functional domains have been defined in NRs. An amino terminal domain is believed to have some regulatory function. A DNA-binding domain hereinafter referred to as "DBD" usually comprises two zinc finger elements and recognizes a specific Hormone Responsive Element hereinafter referred to as "HRE" within the promoters of responsive genes. Specific amino acid residues in the "DBD" have been shown to confer DNA sequence binding specificity (Schena, M. & Yamamoto, K.R., Mammalian Glucocorticoid Receptor Derivatives Enhance Transcription in Yeast, *Science*, 241:965-967, 1988). A Ligand-binding-domain hereinafter referred to as "LBD" is at the carboxy-terminal region of known NRs. In the absence of hormone, the LBD of some but not all NRs appears to interfere with the interaction of the DBD with its HRE. Hormone binding seems to result in a conformational change in the NR and thus opens this interference (Brzozowski et al., Molecular basis of agonism and antagonism in the oestrogen receptor, *Nature*, 389, 753 – 758, 1997; Wagner et al., A structural role for hormone in the thyroid hormone receptor, *Nature*, 378, 690 – 697, 1995). A NR without the HBD constitutively activates transcription but at a low level.

Coactivators or transcriptional activators are proposed to bridge between sequence specific transcription factors and the basal transcription machinery and in addition to influence the chromatin structure of a target cell. Several proteins like SRC-1, ACTR, and Grip1 interact with NRs in a ligand enhanced manner (Heery et al., A signature motif in transcriptional coactivators mediates binding to nuclear receptors, *Nature*, 387, 733 – 736; Heinzel et al., A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression, *Nature* 387, 43 – 47, 1997). Furthermore, the physical interaction with repressing receptor-interacting proteins or corepressors has been demonstrated (Xu et al., Coactivator and Corepressor complexes in nuclear receptor function, *Curr Opin Genet Dev*, 9 (2), 140 – 147, 1999).

Nuclear receptor modulators like steroid hormones affect the growth and function of specific cells by binding to intracellular receptors and forming nuclear receptor-ligand complexes. Nuclear receptor-hormone complexes then interact with a hormone response element (HRE) in the control region of specific genes and alter specific gene expression.

The term LXR (Liver X Receptor) includes all subtypes of this receptor. Specifically LXR includes LXRA (also known as LXRA α , RLD-1 and NR1H3) and LXR β (also known as LXR β , NER, NER1, UR, OR-1, R1P15 and NH1H2) and ligands of LXR should be under-

stood to include ligands of LXRA or LXRb. LXR is a prototypical type 2 nuclear receptor which activates genes upon binding to promoter region of target genes in a prototypical heterodimeric fashion with Retinoid X Receptor (hereinafter RXR, Forman et al., Cell, 81, 687-93, 1995). The relevant physiological ligands of LXR seem to be oxidized derivatives of cholesterol, including 22-hydroxycholesterol and 24,25(S)-epoxycholesterol (Lehmann, et al., Biol. Chem. 272(6), 3137-40, 1997). The oxysterol ligands bound to LXR were found to regulate the expression of several genes that participate in cholesterol metabolism (Janowski, et al., Nature, 383, 728-31, 1996).

LXR is proposed to be a hepatic oxysterol sensor. Upon activation (e.g. binding of oxysterols) it influences the conversion of dietary cholesterol into bile acids by upregulating the transcription of key genes which are involved in bile acid synthesis such as CYP7A1. Hence, activation of LXR in the liver could result in an increased synthesis of bile acids from cholesterol which could lead to decreased levels of hepatic cholesterol. This proposed LXR function in hepatic cholesterol metabolism was experimentally confirmed using knockout mice. Mice lacking the receptor LXRA lost their ability to respond normally to an increase in dietary cholesterol and did not induce transcription of the gene encoding CYP7A1. This resulted in accumulation of large quantities of cholesterol in the livers and impaired hepatic function. (Peet, et al., Cell, 93, 693-704, 1998).

Besides its important function in liver, LXR plays an important role in the regulation of cholesterol homeostasis in macrophages and intestinal mucosa cells where it upregulates cholesterol transporters from the ABC (=ATP binding cassette) family of membrane proteins (Repa, et al., J Biol Chem. 2002 May 24;277(21):18793-800). These transporters are believed to be crucially involved in the uptake of cholesterol from the diet since mutations in their genes leads to diseases such as sitosterolemia (Berge, et al., Science (2000);290(5497):1771-5.).

Other members of the ABC transporter family seem to be responsible for the efflux of cholesterol from loaded macrophages, a process which is thought to prevent the generation of atherosclerotic lesions. Stimulation of LXR by synthetic ligands might result in an increased cholesterol efflux from macrophages and a decreased deposition of atherosclerotic plaques (Venkateswaran, et al., PNAS (2000) 24;97(22):12097-102; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7; Joseph, et al., PNAS (2002);99(11):7604-9).

However, in animal studies it was observed that activation of LXR in the liver by full agonists does not only increase bile acid synthesis but also stimulates the de novo synthesis of fatty acids and triglycerids through the upregulation of key enzymes such as Fatty Acid Synthase (FAS) or Stearyl-CoA Desaturase (SCD-1). (Schultz, et al., Genes Dev (2000) 14(22):2831-8.

Therefore, an ideal synthetic LXR binding compound should have properties that retain the agonistic activity on hepatic bile acid formation and ABC-transporter -mediated decrease in cholesterol uptake from the diet and increased cholesterol efflux from macrophages. In parallel such a compound should lack the hyperlipidemic potential which is exerted through increased fatty acid and tricycleride synthesis.

To date few compounds have been described which bind the LXR receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor (Collins, et al., J Med Chem. (2002) 45(10):1963-6; Schultz, et al., Genes Dev (2000) 14(22):2831-8; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7).

It was thus an object of the present invention to provide for compounds which by means of binding the LXR receptor act as agonist, antagonist or mixed agonist / antagonist of said receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor.

It was further an object of the invention to provide for compounds that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It was also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, obesity and diabetes.

SUMMARY OF THE INVENTION

The present invention provides, *inter alia*, novel LXR nuclear receptor protein binding compounds according to the general formula (1) shown below. Said compounds are also binders of mammalian homologues of said receptor. Further the object of the invention was solved by


providing for amongst the LXR nuclear receptor protein binding compounds according to the general formula (1) such compounds which act as agonists, antagonists or mixed agonists / antagonists of the human LXR receptor or a mammalian homologue thereof.

The invention provides for LXR agonists that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It was also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, obesity and diabetes.

The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention provides for a compound according to the following formula (1), or pharmaceutical acceptable salts or solvates thereof, hereinafter also referred to as the "compounds according to the invention" including particular and preferred embodiments thereof, wherein



R₁, R₂, R₃ and/or R₄, is independently from each other selected from H, halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ al-

kyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N- (phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results. R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₇ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₆ and R₇ may be taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl ring.

The compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

The symbol "H" denotes a hydrogen atom.

The term "C₁ to C₇ acyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, benzoyl and the like. Preferred acyl groups are acetyl and benzoyl.

The term "C₁ to C₇ substituted acyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, nitro, C₁ to C₆ alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N,N-di(C₁ to C₆ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₄ alkylthio or C₁ to C₄ alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to

C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.

Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2, 3 or 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n-propyl)phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4-(isopropoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono-or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 2, 3 or 4-(N-(methylsulfonylamino))phenyl. Also, the term "substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

The term "heteroaryl" means a heterocyclic aromatic derivative which is a five-membered or six-membered ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.

Examples of heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, thiopheno, oxazolo, isoxazolo, phthalimido, thiazolo and the like.

The term "substituted heteroaryl" means the above-described heteroaryl is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino groups.

The term "substituted naphthyl" specifies a naphthyl group substituted with one or more, and preferably one or two, moieties either on the same ring or on different rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino.

Examples of the term "substituted naphthyl" includes a mono or di(halo)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and the like; a mono or di(hydroxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected-hydroxy derivatives thereof and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanonaphthyl group, for example, 1, 2, 3, 4, 5, 6, 7 or 8-cyanonaphthyl; a mono- or di(alkyl)naphthyl group such as 2, 3, 4, 5, 6, 7 or 8-methylnaphthyl, 1, 2, 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropyl)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(n-propyl)naphthyl and the like; a mono or

di(alkoxy)naphthyl group, for example, 2, 6-dimethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-methoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropoxy)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(t-butoxy)naphthyl, 3-ethoxy-4-methoxynaphthyl and the like; 1, 2, 3, 4, 5, 6, 7 or 8-trifluoromethylnaphthyl; a mono- or dicarboxynaphthyl or (protected carboxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-carboxynaphthyl or 2, 4-di(-protected carboxy)naphthyl; a mono- or di(hydroxymethyl)naphthyl or (protected hydroxymethyl)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(protected hydroxymethyl)naphthyl or 3, 4-di(hydroxymethyl)naphthyl; a mono- or di(amino)naphthyl or (protected amino)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(amino)naphthyl or 2, 4-(protected amino)-naphthyl, a mono- or di(aminomethyl)naphthyl or (protected aminomethyl)naphthyl such as 2, 3, or 4-(aminomethyl)naphthyl or 2, 4-(protected aminomethyl)-naphthyl; or a mono- or di-(N-methylsulfonylamino) naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(N-methylsulfonylamino)naphthyl. Also, the term "substituted naphthyl" represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-1-yl, 3-chloro-4-hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-1-yl, 4-ethyl-2-hydroxynaphth-1-yl, 3-hydroxy-4-nitronaphth-2-yl, 2-hydroxy-4-chloronaphth-1-yl, 2-methoxy-7-bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-1-yl and the like.

The term "C₁ to C₈ alkyl" denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 2-methyl-1-hexyl, 2-methyl-2-hexyl, 2-methyl-3-hexyl, n-octyl and the like.

Examples of the above substituted alkyl groups include the 2-oxo-prop-1-yl, 3-oxo-but-1-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyloxymethyl, trityloxymethyl, propionyloxymethyl, amino, methylamino, aminomethyl, dimethylamino, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylaminomethyl, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1-bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1-iodoethyl, 2-iodoethyl, 1-chloropropyl, 2-chloropropyl, 3-chloropropyl, 1-bromopropyl, 2-bromopropyl, 3-bromopropyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1-iodopropyl, 2-iodopropyl, 3-iodopropyl, 2-aminoethyl, 1-aminoethyl, N-benzoyl-2-aminoethyl, N-acetyl-2-aminoethyl, N-benzoyl-1-aminoethyl, N-acetyl-1-aminoethyl and the like.

The term "C₁ to C₈ substituted alkyl" denotes that the above C₁ to C₈ alkyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C₃ to C₇ cycloalkyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N,N-di(C₁ to C₆ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₄ alkylthio or C₁ to C₄ alkylsulfonyl groups. The substituted alkyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

The term "C₇ to C₁₂ phenylalkyl" denotes a C₁ to C₆ alkyl group substituted at any position by a phenyl, substituted phenyl, heteroaryl or substituted heteroaryl. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3-phenyl(n-amyl), 3-phenyl(sec-butyl) and the like. Preferred C₇ to C₁₂ phenylalkyl groups are the benzyl and the phenylethyl groups.

The term "C₇ to C₁₂ substituted phenylalkyl" denotes a C₇ to C₁₂ phenylalkyl group substituted on the C₁ to C₆ alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-(C₁ to C₆ dialkyl)carboxamide, cyano, N-(C₁ to C₆ alkylsulfonyl)amino, thiol, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino,

protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl) carboxamide, protected N-(C₁ to C₆ alkyl) carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, cyclic C₂ to C₇ alkylene or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. The substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.

Examples of the term "C₇ to C₁₂ substituted phenylalkyl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n-hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)- 3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl and the like.

As outlined above R₆ and R₇ may be taken together with nitrogen to form a heterocycle or substituted heterocycle of the following kind aziridine, azetidine, pyrrolidine, 3-methylpyrrolidine, 3-aminopyrrolidine, 3-hydroxypyrrolidine, pyrazolidine, imidazolidine, piperidine, 2-methylpiperidine, piperazine, morpholine, azepine, tetrahydroisoquinoline

The term "heterocycle" or "heterocyclic ring" denotes optionally substituted five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, 2-amino-imidazolyl, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexylmethyleneimino and heptylmethyleneimino.

The term "substituted heterocycle" or "substituted heterocyclic ring" means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₁₂ alkyl, C₁ to C₁₂ alkoxy, C₁ to C₁₂ substituted alkoxy, C₁ to C₁₂ acyl, C₁ to C₁₂ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino carbox-

amide, protected carboxamide, N-(C₁ to C₁₂ alkyl)carboxamide, protected N-(C₁ to C₁₂ alkyl)carboxamide, N, N-di(C₁ to C₁₂ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₁₂ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, heterocycle or substituted heterocycle groups.

The term "C₁ to C₈ alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy. The term "C₁ to C₈ substituted alkoxy" means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C₁ to C₈ substituted alkyl.

The term "C₁ to C₈ aminoacyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, benzoyl and the like.

The term "C₁ to C₈ substituted aminoacyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₁₂ alkoxy, C₁ to C₁₂ acyl, C₁ to C₁₂ acyloxy, nitro, C₁ to C₁₂ alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₁₂ alkyl)carboxamide, protected N-(C₁ to C₁₂ alkyl)carboxamide, N,N-di(C₁ to C₁₂ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₁₀ alkylthio or C₁ to C₁₀ alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

Examples of C₁ to C₈ substituted acyl groups include 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2-cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl.

This invention provides a pharmaceutical composition comprising an effective amount of a compound according to the invention. Such compounds can be administered by various routes, for example oral, subcutaneous, intramuscular, intravenous or intracerebral. The preferred route of administration would be oral at daily doses of the compound for adult human treatment of about 0.01 -5000 mg, preferably 1-1500 mg per day. The appropriate dose may be administered in a single dose or as divided doses presented at appropriate intervals for example as two, three four or more subdoses per day.

For preparing pharmaceutical compositions containing compounds of the invention, inert, pharmaceutically acceptable carriers are used. The pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is generally a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

For preparing pharmaceutical composition in the form of suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.

Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient. Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.

The pharmaceutical compositions can include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner, cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.


Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration. Sterile water solutions of the active component or sterile solutions of the active component in sol-

vents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.

Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.

In one embodiment of the present invention a compound is claimed according to formula (1) above, or pharmaceutical acceptable salts or solvates thereof, wherein R_1, R_2, R_3, R_4 , is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C_1 to C_6 alkyl, C_1 to C_6 substituted alkyl, C_1 to C_7 alkoxy, C_1 to C_7 substituted alkoxy, C_1 to C_7 acyl, C_1 to C_7 substituted acyl, C_1 to C_7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, $N-(C_1 \text{ to } C_6 \text{ alkyl})$ carboxamide, protected $N-(C_1 \text{ to } C_6 \text{ alkyl})$ carboxamide, $N, N\text{-di}(C_1 \text{ to } C_6 \text{ alkyl})$ carboxamide, trifluoromethyl, $N-((C_1 \text{ to } C_6 \text{ alkyl})\text{sulfonyl})$ amino, $N\text{-(phenylsulfonyl)}$ amino or phenyl, R_5 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkyl-phenyl or C_7 to C_{12} substituted phenylalkyl, R_6 and R_7 may be taken together with nitrogen to form the heterocycle according to formula (2),

formula (2)




In a preferred embodiment of the invention a compound is provided, or pharmaceutical acceptable salts or solvates thereof, wherein R_1, R_2, R_3, R_4 , is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C_1 to C_6 alkyl, C_1 to C_6 substituted alkyl, C_1 to C_7 alkoxy, C_1 to C_7 substituted alkoxy, C_1 to C_7 acyl, C_1 to C_7 substituted acyl, C_1 to C_7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, $N-(C_1 \text{ to } C_6 \text{ alkyl})$ carboxamide, pro-

tected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N- (phenylsulfonyl)amino or phenyl, R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, R₆ and R₇ may be taken together with nitrogen to form the heterocycle according to formula (2) shown above.


A particularly preferred compound which may act as agonist of LXR is shown in formula (6) below. The inventors have been able to demonstrate that the compound according to formula (3) has a low effective concentration at LXR with an EC₅₀ of 0.5 μ M wherein the EC₅₀ reflects the half-maximal effective concentration, and which is higher than the EC₅₀ of 0.015 μ M for the published LXR agonist TO901317 (J. Schultz et al., Genes Dev. 14, 2831-2838, 2000)

formula (3) (MOLNAME 3252)




The inventors have also found the compounds according to formula (4, 5 and 6) (shown below) to be active as agonist of the LXR human nuclear receptor (see figures for details).


formula (4) (MOLNAME 7459)



formula (5) (MOLNAME 6584)



formula (6)) (MOLNAME 7364)



In particular the invention relates to a compound as described above wherein said compounds is capable of binding the LXR receptor protein or a portion thereof according to SEQ ID NO. 1 (Fig. 3 A to F) or a mammalian homologue thereof. The claimed compound can bind to the LXR receptor protein or a portion thereof in a mixture comprising 10-200 ng of LXR receptor protein, a fusion protein containing LXR or a portion thereof, preferably the ligand binding domain, fused to a Tag, 5-100 mM Tris /HCl at pH 6,8-8,3 ; 60-1000 mM KCl; 0-20 mM MgCl₂; 100-1000ng/ μ l BSA in a total volume of preferably about 25 μ l.).

A mammalian receptor protein homologue of the protein according to SEQ ID NO. 1 as used herein is a protein that performs substantially the same task as LXR does in humans and shares at least 40% sequence identity at the amino acid level, preferably over 50 % sequence identity at the amino acid level more preferably over 65 % sequence identity at the amino acid level, even more preferably over 75 % sequence identity at the amino acid level and most preferably over 85 % sequence identity at the amino acid level.

The invention in particular concerns a method for prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention wherein the prevention or treatment is directly or indirectly accomplished through

the binding of a compound according to the invention to the LXR receptor protein or to the LXR receptor protein homologue.

The term mediated herein means that the physiological pathway in which the LXR receptor protein acts is either directly or indirectly involved in the disease or condition to be treated or prevented. In the case where it is indirectly involved it could be that, e.g. modulating the activity of LXR by a compound according to the invention influences a parameter which has a beneficial effect on a disease or a condition. One such example is that modulation of LXR activity leads to decreased levels of serum cholesterol or certain lipoproteins which in turn have a beneficial effect on the prevention and treatment of atherosclerosis. Herein a condition is a physiological or phenotypic state which is desirably altered. One such example would be obesity which is not necessarily medically harmful but nonetheless a non desirable phenotypic condition. In a preferred embodiment of the invention the method for prevention or treatment of a LXR receptor protein mediated disease or condition is applied to a human. This may be male or female.

Pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 µg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, doses is from about 100 µg/kg to about 5 mg/kg body weight, daily.

For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of active agent will be 0,1 mg/kg to 10 mg/kg and typically around 1 mg/kg.

By "therapeutically effective amount" is meant a symptom- alleviating or symptom -reducing amount, a cholesterol-reducing amount, a cholesterol absorption blocking amount, a protein and/or carbohydrate digestion-blocking amount and/or a de novo cholesterol biosynthesis-blocking amount of a compound according to the invention.

Likewise, the invention concerns a method of treating in mammal a disease which is correlated with abnormal cholesterol, triglyceride, or bile acid levels or deposits comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention.

Accordingly, the compounds according to the invention may also be used as a method of prevention or treatment of mammalian atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or cardiovascular disorders such as coronary heart disease or stroke.

The invention further concerns a method of blocking in a mammal the cholesterol absorption in the intestine in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention. The invention may also be used to treat obesity in humans.

The Liver X Receptor alpha is a prototypical type 2 nuclear receptor meaning that it activates genes upon binding to the promoter region of target genes in a heterodimeric fashion with Retinoid X Receptor. The relevant physiological ligands of LXR are oxysterols. The present compounds according to the invention have been demonstrated to have a high binding efficacy (binding coefficients measured as EC₅₀ in the range 100 nM to 1500 nM) as well as agonistic and / or antagonistic properties. Consequently they may be applied to regulate genes that participate in bile acid, cholesterol and fatty acid homeostasis as well as other downstream regulated genes. Examples of such genes are but are not limited to lipid absorption, cholesterol biosynthesis, cholesterol transport or binding, bile acid transport or binding, proteolysis, amino acid metabolism, glucose biosynthesis, protein translation, electron transport, and hepatic fatty acid metabolism. LXR often functions in vivo as a heterodimer with the Retinoid X Receptor. Published LXR agonists such as the Tularik compound "TO901317" (See figure 5) are known to influence the regulation of various liver genes. Genes found to be regulated by TO901317 can be found in figure 6. Thus, the invention also concerns a method of modulating a gene whose expression is regulated by the LXR receptor in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention to said mammal.

A number of direct and indirect LXR target genes have been described whose regulated expression contribute to cholesterol homeostasis and lipogenesis. In this respect the direct regulation of Cyp7A, which was shown to be a direct target gene of LXR at least in the rodent lineage is an important aspect of cholesterol removal by increased metabolism of bile acids (Lehmann et al., J Biol.Chem. 272 (6) 3137-3140; 1007). Gupta et al. (Biochem. Biophys Res.Com, 293; 338-343, 2002) showed that LXR α regulation of Cyp7A is dominant over FXR inhibitory effects on Cyp7A transcription.

A key transcription factor that was also shown to be a direct target gene for the LXR receptor is SREBP-1C (Repa et al., Genes and Development, 14:2819-2830; 2000; Yoshikawa et al.; Mol.Cell.Biol.21 (9) 2991-3000, 2001). SREBP-1C itself activates transcription of genes involved in cholesterol and fatty acid synthesis in liver but also other mammalian tissues. Some of the SREBP1c target genes involved in lipogenesis like FAS and SCD have shown to be additionally direct targets of the LXR receptors (Joseph et al.; J Biol Chem. 2002 Mar 29;277(13):11019-25; Liang et al., J Biol Chem. 2002 Mar 15;277(11):9520-8.).

Another gene that has been shown to be directly regulated by LXRs is the LPL gene, that codes for a key enzyme that is responsible for the hydrolysis of triglycerides in circulating lipoprotein, releasing free fatty acids to peripheral tissues. (Zhang et al. J Biol Chem. 2001 Nov 16;276(46):43018-24.) This enzyme is believed to promote uptake of HDL cholesterol in liver, thereby promoting reverse cholesterol transport. A similar functional involvement in HDL clearance is described for the CETP gene product that facilitated the transfer of HDL cholesterol esters from plasma to the liver. LXR response elements were found in the CETP promoter and direct activation of this gene by LXR was demonstrated (Luo and Tall; J Clin Invest. 2000 Feb;105(4):513-20.).

The regulated transport of cholesterol through biological membranes is an important mechanism in order to maintain cholesterol homeostasis. A pivotal role in these processes in multiple tissues like e.g. macrophages and intestinal mucosa cells is maintained by the ATP-binding cassette transporter proteins (ABC). ABCA1 and ABCG1 were identified as direct LXR target genes (Costet et al.; J Biol Chem. 2000 Sep 8;275(36):28240-5) that mediate cholesterol efflux and prevent thereby e.g. generation of artherogenic plaques in macrophages (Singaraja et al. J Clin Invest. 2002 Jul;110(1):35-42). Other ABC transporters like ABCG5

and ABCG8, primarily expressed in hepatocytes and enterocytes have also been reported to be directly responsive to LXR agonists (Repa et al., J Biol Chem. 2002 May 24;277(21):18793-800. Kennedy et al., J Biol Chem. 2001 Oct 19;276(42):39438-47) and mediate the secretion of sterols from the liver and efflux of dietary sterols from the gut.

Apolipoproteins E, C-I, C-II, and C-IV, that fulfill important roles in lipoprotein/lipid homeostasis have also been shown to be direct targets of the LXR receptor (Laffitte et al., Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):507-12; Mak et al.; J Biol Chem. 2002 May 24 [epub ahead of print]). These proteins have been found to be crucial components of chylomicrons, VLDL, IDL, and HDL and are among other things associated with hypertriglyceridemia and arteriosclerosis.

Recently the LXR α itself was shown to be regulated by both LXR receptors in human cell types including macrophages suggesting an autoregulatory amplification event in the response to LXR ligands which could e.g. lead to an enhanced stimulation of LXR target genes like e.g. ABCA1 (Bolten et al.; Mol Endocrinol. 2002 Mar;16(3):506-14.; Laffitte et al., Mol Cell Biol. 2001 Nov;21(22):7558-68; Whitney et al.; J Biol Chem. 2001 Nov 23;276(47):43509-15).

Besides the important function of LXR receptors in tissues like liver and macrophages it has recently been reported that stimulation of epidermal differentiation is mediated by Liver X receptors in murine epidermis. Differentiation marker genes like involucrin, loricin and profilaggrin have been shown to be upregulated upon LXR ligand treatment (Kömüves et al.; J Invest Dermatol. 2002 Jan;118(1):25-34.).

Another recent report describes the regulation of cholesterol homeostasis (primarily the regulation of ABCA1, ABCG1 and SREBP-1C) by the LXR receptors in the central nervous system suggesting that LXRs may prove beneficial in the treatment of CNS diseases such as Alzheimer's and Niemann-Pick disease that are known to be accompanied by dysregulation of cholesterol balance (Whitney et al.; Mol Endocrinol. 2002 Jun;16(6):1378-85).

Therefore one important embodiment the invention concerns are methods that enhances or suppresses amongst other today yet unknown LXR target genes the above mentioned genes

and the associated biological processes and pathways through LXR compounds that are subject of this invention.

The compounds according to the invention may be used as medicaments, in particular for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to the invention to the LXR receptor protein or LXR receptor protein homologue. These pharmaceutical compositions contain 0,1 % to 99,5 % of the compound according to the invention, more particularly 0,5 % to 90 % of the compound according to the invention in combination with a pharmaceutically acceptable carrier.

The invention concerns also the use of a compound according to the invention for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein mediated disease or condition wherein the mammal described above is a human. The medicament may be used for regulating the cholesterol transport system, for regulating levels of cholesterol, triglyceride, and/or bile acid in a mammal preferentially a human by activating the LXR receptor. The medicament may be used for the treatment of atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or a cardiovascular disorder.

The further concerns the use of a compound according to the invention for the manufacture of a medicament capable for blocking in a mammal, preferentially a human the cholesterol absorption in the intestine. Further the claimed compound may be used for the manufacture of a medicament for treating obesity in humans and for modulating a gene whose expression is regulated by the LXR receptor (see details above and figures).

The present invention shall now be further illustrated based on the following examples without being limited thereto. In the accompanying sequence protocol and the figures:

SEQ ID NO. 1 shows protein sequence of the LRX alpha protein a portion of which was used for cloning as described in the examples,

SEQ ID NO. 2 shows the mRNA sequence of the LRX alpha protein,

SEQ ID NO. 3 shows the protein sequence of TIF2 (Acc. No: XM_011633 RefSeq DB),

SEQ ID NO. 4 shows the respective mRNA sequence corresponding to the TIF2 protein,

SEQ ID NO 5 shows the protein sequence of the LXR beta protein a portion of which was used for cloning as described in examples,

SEQ ID NO 6 shows the mRNA sequence of the LXR beta protein,

SEQ ID NO 7 shows the sequence of primer (a) used in Example 1

SEQ ID NO 8 shows the sequence of primer (b) used in Example 1.

Fig. 1 shows the synthesis of the compounds according to the invention as also described in Example 2.

Fig. 2 shows the measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter which was used for measuring the EC₅₀ values

Fig. 3 A shows SEQ ID NO. 1 which is the protein sequence of the LRX alpha protein a portion of which was used for cloning as described in the examples . Figure 3 B shows SEQ ID NO. 2 which is the mRNA sequence of the LRX alpha protein. Figure 3 C shows SEQ ID NO. 3 which is the protein sequence of TIF2 (Acc. No: XM_011633 RefSeq DB), Figure 3 D shows SEQ ID NO. 4 which is the respective mRNA sequence corresponding to the TIF2 protein. Figure 3 E shows SEQ ID NO 5 which is the protein sequence of the LXR beta protein a portion of which was used for cloning as described in examples. Figure 3 F shows SEQ ID NO 6 which is the mRNA sequence of the LXR beta protein.

Fig. 4 shows the internal molecular name used by the applicant (MOLNAME) as well as the corresponding structures of preferred compounds according to the invention. The figure further shows their respective EC₅₀ values (EC50 AVG) as established according to the experiment 1 in multiple experiments (see above), as well as their respective average efficacy (% activity relative to 22-(R)-hydroxycholesterol control agonist).

Figure 5 shows various known LXR ligands. It is apparent from their structures that the inventors have identified novel compounds which are structurally not related to these known ligands.

Figure 6 shows various genes that have been found to be regulated through binding of an LXR agonist to the LXR protein.

Figure 7 shows a dose-dependent transactivation ($EC_{50} \sim 3 \mu M$) by LN0000007465 of the luciferase reporter gene via LXR alpha.

Figure 8 shows (A) Analysis of mRNA content of the indicated genes in total RNA isolated from THP-1 cells treated for 24 hours with 2, 10 or 25 μM of LN0000006500 or 10 μM of the Tularik compound (T0901317). (B) Analysis of mRNA content for the indicated genes in total RNA from HepG2 cells treated for 24 hours with 2, 10 or 25 μM of LN0000006500 or 10 μM of the Tularik compound (T0901317).

Figure 9 shows the dose dependent transactivation by LN0000006500 of the pFR-luc reporter gene in CHO cells via Gal4 LBD-fusion constructs derived from LXRA- or LXRB. Concentrations of the compound administered (μM) and RLU's determined from extracts of cells are indicated.

Figure 10 shows the analysis of total cholesterol from supernatants of cultivated THP-1 cells incubated without or with ApoA1 and ApoA1 plus 10 μM of the compounds Tularik (T0901317) or LN0000006500, LN0000006662, LN0000006671 or LN0000006672 as indicated.

EXAMPLES

EXAMPLE 1:

In vitro screening for compounds which influence LXR binding to coactivators.

For screening purposes a GST and 6 x His fusion of the LBD (from amino acids 155 of hLXRalpha to 447) of human LXRalpha was constructed by first cloning a Gateway cassette (Invitrogen) in frame into the Sma I site of the pAGGHLT Polylinker (Pharmingen). Then a PCR fragment specifically amplified from human liver cDNA was cloned into the resulting

pACGHLT-GW following the manufacturers instructions for Gateway cloning (Invitrogen) to yield pACGHLT-GW-hLXRalphaLBD.

Primers used for amplification were: primer (a) GGGGACAAGTTTGTACAAAAAAGCAGGCTCGCTTCGCAAATGCCGTCAG (SEQ ID NO 7), and primer (b) GGGGACCACTTTGTACAAGAAAGCTGGGTCCCCTTCTCAGTCTGTTCCACTT (SEQ ID NO 8).

100 % sequence integrity of all recombinant products was verified by sequencing. Recombinant Baculovirus was constructed from pACGHLT-GW-hLXRalphaLBD using the Pharmingen Baculovirus Expression vector system according to instructions of the manufacturer. Monolayer cultures of SF9 cells were infected by the virus as recommended by Pharmingen or 200ml cultures of 1×10^6 cells/ml grown in 2 liter Erlenmeyer flasks on an orbital shaker at 30 rpm were infected by 10ml of same virus stock. In both cases cells were harvested 3 days after infection. All cell growth was performed in Gibco SF900 II with Glutamine (Invitrogen) medium without serum supplementation at 28°C. Since SF9 cells contain significant amounts of endogenous GST, purification was performed via His and not via GST affinity chromatography. To this end instructions of Pharmingen for purification of recombinant His tagged proteins from SF9 cells were followed with the following modifications: All detergents were omitted from the buffers and cells were lysed on ice by 5 subsequent sonication pulses using a sonicator needle at maximum power.

All eluates were dialyzed against 20 mM Tris/HCl pH 6,8, 300 mM KCl; 5 mM MgCl₂; 1 mM DTT; 0,2 mM PMSF; 10% Glycerol. A typical dialyzed eluate fraction contained the fusion protein at a purity of more than 80%. Total protein concentration was 0,1-0,3 mg/ml.

For E. coli expression of a NR coactivator, pDest17-hTif2BD expressing a NR interaction domain from amino acids 548-878 of human Tif2 (Acc. No: XM_011633 RefSeq) tagged by 6 N-terminal His residues was constructed. Therefore, a PCR fragment specifically amplified from human liver cDNA was subcloned into pDest 17 (Invitrogen) following the manufacturers instructions for Gateway cloning (Invitrogen). Primers used for Amplification were: primer (a)

GGGGACAAGTTTGTACAAAAAAGCAGGCTCGTTAGGGTCATCGTTGGCTTCACC

and primer (b)
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAAGTTGCCCTGGTCGTGGGTTA

For E. coli expression plasmid DNA was transformed into chemically competent E. coli BL21 (Invitrogen, USA) and cells were grown to an OD600 of 0.4-0.7 before expression was induced by addition of 0,5 mM IPTG according instructions of the manufacturer (Invitrogen). After induction for 8 hours at 30°C cells were harvested by centrifugation for 10 minutes at 5000 x g. Fusion proteins were affinity purified using Ni-NTA Agarose (QIAGEN) according to the instructions of the manufacturer. Recombinant Tif2 construct was dialyzed against 20 mM Tris/HCL pH 7.9; 60 mM KCl; 5 mM MgCl₂; 1 mM DTT, 0,2 mM PMSF; 10% glycerol. A typical dialyzed eluate fraction contained the fusion protein at a purity of more than 80%. Total protein concentration was 0,1-0,3 mg/ml.

The TIF2 fragment was subsequently biotinylated by addition of 5-40µl/ml Tif2 fraction of a Biotinamidocaproate N-Hydroxysuccinimide-ester (Sigma) solution (20 mg/ml in DMSO). Overhead rotating samples were incubated for 2 hours at room temperature. Unincorporated label was then separated using G25 Gel filtration chromatography (Pharmacia Biotech, Sweden). Protein containing fractions from the column were pooled and tested for activity in the assay as described below.

For screening of compound libraries as provided for by the methods shown below in the examples for substances which influence the LXR/Tif 2 interaction, the Perkin Elmer LANCE technology was applied. This method relies on the binding dependent energy transfer from a donor to an acceptor fluorophore attached to the binding partners of interest. For ease of handling and reduction of background from compound fluorescence LANCE technology makes use of generic fluorophore labels and time resolved detection (for detailed description see Hemmilä I, Blomberg K and Hurskainen P, Time-resolved resonance energy transfer (TR-FRET) principle in LANCE, Abstract of Papers Presented at the 3 rd Annual Conference of the Society for Biomolecular Screening, Sep., California (1997))

For screening, 20-200 ng of biotinylated Tif 2 fragment and 10-200 ng of GST-LXR fragment were combined with 0.5-2 nM LANCE Eu-(W1024) labelled anti-GST antibody (Perkin Elmer) and 0,1-0,5µg of highly fluorescent APC-labelled streptavidin (Perkin Elmer,

AD0059) in the presence of 50 μ M of individual compounds to be screened in a total volume of 25 μ l of 20 mM Tris /HCl pH 6,8; 300 mM KCl; 5 mM MgCl₂; 100-1000 ng/ μ l/ BSA. DMSO content of the samples was kept below 4%. Samples were incubated for a minimum of 60 minutes in the dark at room temperature in FIA-Plates black 384well med. binding (Greiner).

The LANCE signal was detected by a Perkin Elmer VICTOR2V™ Multilabel Counter applying the detection parameters listed in Fig. 2. The results were visualized by plotting the ratio between the emitted light at 665 nm and at 615 nm. For every batch of recombinant proteins amount of proteins, including BSA and labeling reagents giving the most sensitive detection of hits was determined individually by analysis of dose response curves for 22R Hydroxycholesterol and TO 901317

EXAMPLE 2:

Experimental procedure for the preparation of the compounds according to the invention.

o-AZIDOBENZOIC ACID SYNTHESIS (2)

The anthranilic acid (1, 1 eq., 0.5-1 M) was suspended in 6 M HCl, containing enough AcOH (0-20% dependent upon the anthranilic acid) to facilitate dissolution of the anthranilic acid and/or the intermediate diazonium salt, and cooled to 0 °C. NaNO₂ (1.1 eq., 1.3-2.5 M) dissolved in H₂O was added to the anthranilic acid solution at a rate such that the temperature of the reaction solution remained below 5 °C. The resulting homogeneous solution of the diazonium salt was slowly filtered through a sintered glass funnel into a solution of NaN₃ (1.1 eq., 0.7-1.1 M) and NaOAc (12 eq.) in H₂O. The reaction mixture was stirred/shaken for 30-60 min following cessation of vigorous N₂ evolution. Following acidification of the reaction mixture to pH 1 with concentrated HCl, the mixture was cooled to 0 °C to encourage complete precipitation of the *o*-azidobenzoic acid. The precipitate was collected by filtration and washed with 6 M HCl (2x) and H₂O (2x). The *o*-azidobenzoic acid product (2) was dried *in vacuo* (500 mtorr, 30 °C).

ACYLATION OF HYDROXYMETHYL RESIN (4)

To hydroxymethyl resin (1.0 eq., 1.3 mmol/g) and the *o*-azidobenzoic acid (1, 2.5 eq.) was added DMF (to give 400 mM *o*-azidobenzoic acid, 1), CsCO₃ (2.0 eq.) and KI (2.0 eq.). Following agitation of the reaction mixture for 36-48 h, the resin-bound *o*-azidobenzoic acid (4)

was washed with MeOH (2 cycles), CH₂Cl₂ (3 cycles), MeOH (3 cycles), DMF (3 cycles), MeOH (3 cycles) and CH₂Cl₂ (3 cycles), and dried *in vacuo*.

AZA-WITTIG FORMATION (5)

To the resin-bound *o*-azidobenzoic acid (4, 1.0 eq.) was added a solution of PPh₃ (THF, 500 mM, 5.0 eq.). After 6 h, the resin was washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH₂Cl₂ (3 cycles) and hexanes (3 cycles). Followed by drying *in vacuo* to afford resin bound iminophosphorane (5)

CARBODIIMIDE FORMATION (6)

To the resin-bound iminophosphorane (5, 1 eq.) was added isocyanate (9, 5 eq., 450 mM) dissolved in ClCH₂CH₂Cl. The compounds were shaken at ambient temperature for 16 h, washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH₂Cl₂ (3 cycles) and hexanes (3 cycles), and dried *in vacuo* to afford carbodiimide (6).

GUANIDINE FORMATION / CYCLIZATION

To the carbodiimide functionalized resin (6) was added secondary amine (10, 0.6 eq., 500 mM) dissolved in ClCH₂CH₂Cl. The reaction mixture was heated to 50 °C in an incubator for 12-72 h to afford 2-aminoquinazoline (8).

All of the final products were analyzed by HPLC using mass and an Evaporative Light Scattering Detector (ELSD) detection to determine purity and identity.

One skilled in the art will be able to arrive at the compounds claimed herein making use of said protocol.

EXAMPLE 3:

This example illustrates that a compound according to the invention (experiments shown were done with MOLSTRUCTURE LN 0000007465 (see figures 4 for structural formula)) can mediate transactivation of LXR mediated transcription in HEK293 cells.

HEK293 cells were grown in 48 well plates and co-transfected with the pTRexDest30 (Invitrogen) derivatives pTRexDest30-hLXR α , pTRexDest30-hRXR β and the pGL2promoter (Promega) derivative pGL2promoter-LXRRE (each 300 ng of plasmid DNA). The full length

human LXR (accession U68233) and the full length human RXR α (accession P19793) were cloned into the pTRexDest30 applying the manufacturer protocols for the GatewayTM system (Invitrogen).

The LXR response elements (LXRRE) were (upper case and underlined) 5'

CccttTGGTCActcaAGTTCAagtgatgatagaattcggatccttTGGTCActcaAGTTCAagtga 3'
(SEQ ID NO. 5) derived from the rat Cyp7a promoter (Laffite et al., 2001, PNAS 98,pp 507). Luciferase reporter activity was measured in triplicates from extracts of cells after incubating cells in culture medium (DMEM [Gibco-BRL] + 10% FCS [PAA laboratories]) for 16 hours (5% CO₂, 37°C) containing 0,5% DMSO (control) or 0,5% DMSO with increasing concentrations of LN0000007465.

A dose-dependent transactivation (EC₅₀ ~ 3 μ M) of the reporter gene by LXRA was observed (Fig. 7).

Example 4:

This example shows that described compounds can increase the abundance of mRNA of target genes for the LXR proteins in THP-1 cells treated with TPA.

THP-1 (3x10⁵ cells per dish) cells were seeded in 24 well dishes in 3 ml modified RPMI-1640 medium (ATTC, Cat.No. 30-2001) containing 10%FCS (GIBCO) and 100nM TPA and cultivated at 37°C in 5% CO₂ for 48 hours. The medium was then removed and replaced with medium containing 10% charcoal/stripped FBS (Hyclone) and incubated with LN0000006500 at 2, 10 or 25 μ M concentration or Tularik (T0901317) at 10 μ M for 24 hours as indicated in Fig 8A as an example. HepG2 (4,5x10⁵ cells per dish) were seeded in 24 well dishes in 3 ml DMEM Medium containing 10%FCS (GIBCO) and cultivated at 37°C in 5% CO₂ for 48 hours as indicated in Fig 8B.

After incubation for 24 hours in presence of compound, total RNA was isolated from the cells using a Quiagen RNAeasy kit (Quiagen) according to the manufacturers protocol. The RNA was then reverse transcribed and analyzed by TaqMan Analysis using kits and equipment from Perkin-Elmer known to those knowledgeable in the field.

The fold change of mRNA abundance of compound treated versus DMSO treated as a control is shown in Figure 8A and B for several analyzed target genes indicated in Figure 8A and B.

Example 5:

This example shows that described compounds can selectively enhance transcription mediated by the LBD's of the respective nuclear receptors LXR α and LXR β .

CHO cells (1×10^5 cells 96well plate) were co-transfected (Lipofectamine 2000 GIBCO) with pFR-luc (Stratagene) as a reporter gene construct and pCMV-AD derivatives containing the LXR α or LXR β ligand binding domains, which were cloned via the gateway system (GIBCO) described in Example 1, in order to express Gal4DBD-LXR α or Gal4DBD-LXR β fusion proteins.

Cells were grown in DMEM containing 10%FCS at 37°C in 5% humidified CO₂ for 16h in presence of 0,05% DMSO vehicle or 0,032 to 50 μ M LN0000006500 in vehicle (as indicated in Fig.9). Luciferase activity was determined from aliquots of extracts prepared from cells following standard luciferase assay kits and protocols from Promega.

Example 6:

This example shows that described compounds at 10 μ M concentration for 24 hours can increase the reverse cholesterol transport in THP-1 cells that were treated with TPA.


THP-1 (1×10^6 cells per dish) cells were seeded in 6 well dishes in 3ml modified RPMI1640 medium (ATTC, Cat.No. 30-2001) containing 10%FCS (GIBCO) and 100nM TPA and cultivated at 37°C in 5% CO₂ for 72 hours. The medium was then removed and replaced with fresh medium containing 100 nM TPA and 0,15 % BSA. After 24 h incubation the cells were washed in PBS and 1,5 ml of fresh medium containing either 0,1% DMSO alone or 0,1% DMSO together with 40 μ g/ml ApoA1 (Calbiochem) or 40 μ g/ml ApoA1 plus the in Fig.10 as an example indicated compounds Tularik (T0901317), LN0000006500, LN0000006662, LN0000006671, LN0000006674 at 10 μ M.

After incubation for 24 hours, total cholesterol was determined from cell supernatant in each of the wells using an enzymatic assay with fluorescence read-out for the determination of cholesterol (Amplex Red Cholesterol Assay Kit (A-12213). The fluorescence readout per mg

of total protein content as determined from cells that were present in the respective well are shown in Figure 9 as an example.

Claims:

1. A compound of the formula (1), or pharmaceutical acceptable salts or solvates thereof according to formula (1)




wherein:

R₁, R₂, R₃ and/or R₄, is independently from each other H, halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl,


R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, and

R₇ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl.

2. A compound according to claim 1 wherein R₆ and R₇ are taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl according to the following formula (2).




3. A compound according to claim 2, or pharmaceutical acceptable salts or solvates thereof, wherein:
- R_1, R_2, R_3, R_4 , is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C_1 to C_6 alkyl, C_1 to C_6 substituted alkyl, C_1 to C_7 alkoxy, C_1 to C_7 substituted alkoxy, C_1 to C_7 acyl, C_1 to C_7 substituted acyl, C_1 to C_7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C_1 to C_6 alkyl)carboxamide, protected N-(C_1 to C_6 alkyl)carboxamide, N, N-di(C_1 to C_6 alkyl)carboxamide, trifluoromethyl, N-((C_1 to C_6 alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, and
- R_5 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl.
4. A compound according to claim 1 wherein R_6 and R_7 are taken together with nitrogen to form the heterocycle according to the following formula (3)




5. A compound according to any of claims 1 to 3 of the following formula (4)

formula (4)




6. A compound according to any of claims 1 to 3 of the following formula (5)

formula (5)




7. A compound according to any of claims 1 to 3 of the following formula (6)

formula (6)




8. A compound according to any of claims 1 and 4 wherein R₆ and R₇ are taken together with nitrogen to form the heterocycle according to the following formula (7)

formula (7)




9. A compound according to claim 1 according to the following formula (8)

formula (8)



10. A compound according to claims 1 and 4 according to the following formula (8)

formula (8)



11. A compound according to any of claims 1 to 10 wherein said compound is capable of binding the NR1H3 receptor protein or a portion thereof according to SEQ ID NO. 1 or a mammalian homologue thereof.
12. A compound according to any of claims 1 to 10 wherein said compound is capable of binding the NR1H2 receptor protein or a portion thereof or a mammalian homologue thereof.
13. Use of a compound according to any of claims 1 to 12 as a medicament
14. A method for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 12, wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according claims 1 to 13 to the NR1H3 and/or NR1H2 receptor proteins or to the NR1H3 and/or NR1H2 receptor protein homologues.
15. A method for prevention or treatment of a NR1H3 receptor protein and/or NR1H2 receptor protein mediated disease or condition according to claim 14, wherein said mammal is a human.

16. A method for regulating the cholesterol synthesis and/or transport in a mammal which comprises activating the NR1H3 and/or NR1H2 receptors with a therapeutically effective amount of a compound according to claims 1 to 12.
17. A method of treating in a mammal a disease which is affected by cholesterol, triglyceride, or bile acid levels comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.
18. A method of treating atherosclerosis, alzheimers disease, lipid disorders, obesity or a cardiovascular disorder in a mammal, in particular a human, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.
19. A method according to any of claims 14 to 18 wherein the expression of ABCA1 and/or ABCG1 and/or ABCG5 and/or ABCG8 is increased.
20. A method according to any of claims claim 14 to 19 wherein the expression of the cholesterol 7 α hydroxylase and/or the activity of the cholesteryl ester transfer protein is increased.
21. A method of blocking in a mammal the cholesterol or fatty acid absorption in the intestine of a mammal in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.
22. A method for treating obesity in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 12.
23. A method of modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor in a mammal comprising administering a therapeutically effective amount of a compound according to claims 1 to 10.

24. A method according to any of claims claim 14 to 19 wherein the expression of the cholesterol 7 α hydroxylase and/or the activity of the cholesteryl ester transfer protein is enhanced.
25. Use of a compound according to any of claims 1 to 12 wherein the mammal is a human
26. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for the prevention or treatment of a NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according claims 1 to 8 to the NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue.
27. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or condition according to claim 26, wherein the mammal is a human.
28. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for regulating the cholesterol transport system in a mammal by activating the NR1H3 and/or NR1H2 receptor.
29. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for regulating levels of cholesterol, triglyceride, and/or bile acid.
30. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for treating in a mammal atherosclerosis, alzheimer disease, gallstone disease, lipid disorders, obesity or a cardiovascular disorder.
31. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament capable for blocking in a mammal the cholesterol and/or fatty acid absorption in the intestine.

32. Use of the compound according to any of claims 1 to 12 for the manufacture of a medicament for treating obesity in a mammal.
33. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor.
34. Use of a compound according to any of claims 1 to 12 in a mammal for the selective up-regulation of one or more genes selected from the group consisting of ABCA1, ABCG1, ABCG5 and ABCG8 and a down-regulation of one or more of the genes selected from the group comprising FAS and SREBP-1c, said compound showing a larger difference in regulation of the two groups of genes when compared with the regulatory behavior of T0901317 on both groups of genes.
35. Use of a compound according to claims 28, 30, 31, 32, and 34 wherein the mammal is a human.

Fig. 2 : Measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter:

| | |
|--|--------------|
| Number of repeats | 1 |
| plate: GREINER FIA-Plate black 384 well med. binding | |
| Measurement height | 3.50 mm |
| Label technology | TR-F Lance |
| Emission filter name | D615 |
| Emission filter slot | A1 |
| Emission aperture | Normal |
| Excitation filter | D340 |
| Delay | 50 μ s |
| Window time | 400 μ s |
| Cycle | 1000 μ s |
| Light integrator capacitors | 1 |
| Light integrator ref. level | 95 |
| Flash energy area | High |
| Flash energy level | 223 |
| Flash absorbance measurement | No |
| Beam | Normal |
| Label technology | TR-F Lance |
| Emission filter name | D665 |
| Emission filter slot | A8 |
| Emission aperture | Normal |
| Excitation filter | D340 |
| Delay | 50 μ s |
| Window time | 400 μ s |
| Cycle | 1000 μ s |
| Light integrator capacitors | 1 |
| Light integrator ref. level | 95 |
| Flash energy area | High |
| Flash energy level | 223 |
| Flash absorbance measurement | No |
| Beam | Normal |

Fig. 3 A and B:

A

```
1 mslwlgapvp dippsavel wkpgaqdass qaqqgsscil reearmphsa ggtagvglea
61 aeptalltra eppsepteir pqkrkkgpap kmnlgnelcsv cgdkasgfhy nvlsccegckg
121 ffrsvikga hyichsgghc pmdtymrrkc qecrlrkcrq agmreecvls eeqlrlkkik
181 rqeeeqahat slpprrspp qilpqlspeq lgmieklvaa qqcnrrsfs drlrvtpwpm
241 apdphsrear qqrfahtel aivsvqeivd fakqlpgflq lsredqiall ktsaievml
301 etsrrypgs esitflkdfs ynredfakag lqvefinpif efsramnelq lndaefalli
361 aisifsadrp nvqdqlqver lqhtyvealh ayvsihphd rlmfprlmk lvsirtlssv
421 hseqvfalrl qdkklppls eiwdvhe
```

B

```
1 atgtccttgt ggctgggggc ccctgtgcct gacattcctc ctgactctgc ggtggagctg
61 tggaagccag gcgcacagga tgcaagcagc caggcccagg gaggcagcag ctgcatcctc
121 agagaggaag ccaggtatgcc ccactctgct gggggtactg cagggttggg gctggaggct
181 gcagagccca cagccctgct caccagggca gagccccctt cagaaccac agagatccgt
241 ccacaaaagc ggaaaaaggg gccagcccc aaaatgtctg ggaacgagct atgcagcgtg
301 tgtggggaca aggcctcggg cttccactac aatgttctga gctgcgaggg ctgcaaggga
361 ttcttccgcc gcagcgtcat caaggagcag cactacatct gccacagtgg cggccactgc
421 cccatggaca cctacatgcy tcgcaagtgc caggagtgtc ggcttcgcaa atgcctcag
481 gctggcatgc gggaggagtg tgcctgtca gaagaacaga tccgctgaa gaaactgaag
541 cggcaagagg aggaacaggc tcatgccaca tccttgcccc ccaggcgttc ctcaccccc
601 caaatcctgc cccagctcag cccggaacaa ctgggcatga tcgagaagct cgtcgtgcc
661 cagcaacagt gtaaccggcg ctcttttct gaccggcttc ggtcacgcc ttggcccatg
721 gcaccagatc cccatagccg ggaggcccg cagcagcgt ttgcccactt cactgagctg
781 gccatcgtct ctgtgcagga gatagttgac tttgctaaac agctaccgg cttcctgcag
841 ctgagccggg aggaccagat tgccctgtct aagacctctg cgatcgaggt gatgcttctg
901 gagacatctc ggaggtacaa ccctgggagt gagagtatca ccttctcaa ggatttcagt
961 tataaccggg aagactttgc caaagcagg ctgcaagtgg aattcatcaa cccatcttc
1021 gagttctcca gggccatgaa tgagctgcaa ctcaatgatg ccgagtttgc cttgctcatt
1081 gctatcagca tcttctctgc agaccggccc aacgtgcagg accagctcca ggtggagagg
1141 ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac
1201 cgactgatgt tcccaggat gctaataaaa ctggtgagcc tccggacct gagcagcgtc
1261 cactcagagc aagtgttgc actgcgtctg caggacaaaa agctcccacc gctgctctct
1321 gagatctggg atgtgcacga atga
```

1431

Fig. 3 C and D:

C

| | | | | | | |
|-------------|-------------|------------|------------|-------------|------------|------|
| MLVKPLPDSE | EEGHDNQEAH | QKYETMQCFA | VSQPKSIKEE | GEDLQSCLIC | VARRVPMKER | 60 |
| PVLPSSESFT | TRQDLQKIT | SLDTSTMRAA | MKPGWEDLVR | RCIQKFHAQH | EGESVSYAKR | 120 |
| HHHEVLROGL | AFSQIYRFSL | SDGTLVAQAT | KSKLIRSQTT | NEPQLVISLH | MLHREQNVCV | 180 |
| MNPDLTGQTM | GKPLNPISSN | SPAHQALCSG | NPGQDMTLSS | NINFPINGPK | EQMGMPMGRF | 240 |
| GGSGGMNHVS | GMQATTPQGS | NYALKMNSPS | QSSPGMNPQG | PTSMLSPRHR | MSPGVAGSPR | 300 |
| IPPSQFSFAG | SLHSPVGVCS | STGNSHSYTN | SSLNALQALS | EGHGVSLGSS | LASPDLMGN | 360 |
| LQNSPVMNMP | PPLSKMGS LD | SKDCFGLYGE | PSEGTGQAE | SSCHPGEQKE | TNDPNLPFAV | 420 |
| SSERADGQSR | LHDSKGQTKL | LQLLTTKSDQ | MEPSPLASSL | SDTNKDSTGS | LPGSGSTHGT | 480 |
| SLKEKHKLILH | RLLQDSSSPV | DLAKLTAEAT | GKDLSEQESS | TAPGSEVTIK | QEPVSPRKKE | 540 |
| NALLRYLLDK | DDTKDIGLPE | ITPKLERLDS | KTDPASNTKL | IAMKTEKEEM | SFEPGDQPGS | 600 |
| ELDNLEEILD | DLQNSQLPQL | FPDTRPGAPA | GSVDKQAIIN | DLMQLTAENS | PVTPVGAQKT | 660 |
| ALRISQSTFN | NPRPQQLGRL | LPNQNLPLDI | TLQSTTGAGP | FPPIRNSPY | SVIPQPGMMG | 720 |
| NQGMIGNQGN | LGNSSGTGMIG | NSASRPTMPS | GEWAPQSSAV | RVTCAATSA | MNRPVQGGMI | 780 |
| RNPAASTPMR | PSSQPGQRTQ | LQSQVMNIGP | SELEMNMGGP | QYSQQOAPPN | QTAPWPESIL | 840 |
| PIDQASFASQ | NRQPFQSSPD | DLCPHPAAE | SPSDEGALLD | QLYLALRNFD | GLEEIDRALG | 900 |
| IPELVSQSQA | VDPEQFSSQD | SNIMLEQKAP | VFPQQYASQA | QMAQGSYSYM | QDPNFHTMGQ | 960 |
| RPSYATLRMQ | PRPGLRPTGL | VONQFNQLRL | QLQHLRLQAO | NRQPLMNQIS | NVSNVNLTLR | 1020 |
| PGVPTQAPIN | AQMLAQORRE | ILNQHLRQQR | MHQQQQVQQR | TLMMRGQGLN | MTPSMVAPSG | 1080 |
| MPATMSNPRI | PQANAQQFPF | PPNYGISQQP | DPGFTGATTP | QSPILMSPRMA | HTQSPMMQOS | 1140 |
| QANPAYQAPS | DINGWAQQNM | GGNSMFSQOS | PPHFGQQANT | SMYSNNNMNIN | VSMATNTGGM | 1200 |
| SSMNQMTGQI | SMTSVTSVPT | SGLSSMGPEQ | VNDPALRGGN | LFPNQLPGMD | MIKQEGDTR | 1260 |
| KYC | | | | | | 1263 |

D

```

1 ggcgcccgca gcctcggcta cagcttcggc ggcaaggtc agcgccgacg gcagccggca
61 cctgacggcg tgaccgaccc gagccgattt ctcttggtt tggctacaca cttatagatc
121 ttctgcactg tttacaggca cagttgctga tatgtgttca agatgagtg gatgggagaa
181 aatacctctg acccctccag ggcagagaca agaaagcgca agaatgtcc tgaccaactt
241 ggaccagacc ccaaaaggaa cactgaaaaa cgtaatcgtg aacaggaaaa taaatatata
301 gaagaacttg cagagttgat ttttgcaaat ttaatgata tagacaactt taacttcaa
361 cctgacaaat gtgcaatctt aaaagaaact gtgaagcaaa ttcgtcagat caaagaacaa
421 gagaaagcag cagctgccaa catagatgaa gtgcagaagt cagatgtatc ctctacaggg
481 caggggtgtc tcgacaagga tgcgctgggg cctatgatgc ttgagggcct tgatgggttc
541 ttctttgtag tgaacctgga aggcaacgtt gtgtttgtg cagagaatgt gacacagtat
601 ctaaggatata accaagaaga gctgatgaac aaaagtgtat atagcatctt gcatgttggg
661 gaccacacgg aatttgtcaa aaacctgctg ccaaaagtcta taggtaaatg ggggatcttg
721 gtctggcgaa cctccgaggg ggaacagcca taccttcaat tgcggatgc tggtaaaacc
781 ttactctgat tcagaagagg agggctcatga taaccaggaa gctcatcaga aatatgaaac
841 tatgcagtgc ttgcgtgtct ctcaaccaa gtccatcaa gaagaaggag aagatttgca
901 gtccctgttg atttgcgttg caagaagagt tcccagaaag gaaagaccag ttctccctc
961 atcagaaagt ttactactc gccaggatct ccaaggcaag atcacgtctc tggataccag
1021 caccatgaga gcagccatga aaccaggctg ggaggacctg gtaagaaggt gtattcagaa
1081 gttccatgag cagcatgaag gagaatctgt gtcctatgct aagaggcatc atcatgaagt
1141 actgagacaa ggattggcat tcagtcacaa ctatcgtttt tcctgtctg atggcactct
1201 tgttgtgtga caaacgaaga gcaaaactcat ccgttctcag actactaatg aacctcaact
1261 tgtaatatct ttacatatgc ttcacagaga gcagaatgtg tgtgtgatga atccggatct
1321 gactggacaa acgatgggga agccactgaa tccaattagc tctaaccagc ctgcccatca
1381 ggccctgtgc agtggggaacc caggtcagga catgaccctc agtagcaata taaatttttc
1441 cataaatggc ccaaaaggaa aatgggcat gcccatgggc aggttttggtg gttctggggg
1501 aatgaacatg gtgtcaggca tgcaagcaac cactcctcag ggtagtaact atgcactcaa
1561 aatgaacagc ccttcacaaa gcagccctgg catgaatcca ggacagccca cctccatgct
1621 ttcaccaagg catcgcatga gccctggagt ggctggcagc cctcgaatcc caccagtc
1681 gttttccctc gcaggaagct tgcattcccc tgtgggagtt tgcagcagca caggaaatag
1741 ccatagttat accaacagct cctcaatgc acttcaggcc ctcagcgagg ggcacgggtg
1801 ctcattaggg tcactgttgg cttcaccaga cctaaaaatg ggcaatttgc aaaactcccc
1861 agttaatatg aatcctcccc cactcagcaa gatgggaagc ttggactcaa aagactgttt
1921 tggactatat ggggagccct ctgaaggtac aactggacaa gcagagagca gctgccatcc
1981 tggagagcaa aaggaacaa atgaccccaa cctgcccccg gccgtgagca gtgagagagc
2041 tgacgggcag agcagactgc atgacagcaa agggcagacc aaactcctgc agctgctgac
2101 caccaaatct gatcagatgg agccctcgcc cttagccagc tctttgtcgg atacaaacaa
2161 agactccaca ggtagcttgc ctggttctgg gtctacacat ggaacctcgc tcaaggagaa
2221 gcataaaatt ttgcacagac tcttcaggga cagcagttcc cctgtggact tggccaagtt
2281 aacagcagaa gccacaggca aagacctgag ccaggagtcg agcagcacag ctccctggatc
2341 agaagtgact attaaacaag agccggtgag ccccaagaag aaagagaatg cactacttcg
2401 ctatttgcta gataaagatg atactaaaga tattgtgtta ccagaaataa ccccaaaact
2461 tgagagactg gacagtgaag cagatcctgc cagtaacaca aaattaatag caatgaaac
2521 tgagaaggag gagatgagct ttgagcctgg tgaccagcct ggcagtgagc tggacaactt
2581 ggagagagatt ttggatgatt tgcagaatag tcaattacca cagcttttcc cagacacgag
2641 gccagcgccc cctgctggat cagttgacaa gcaagccatc atcaatgacc tcatgcaact
2701 cacagctgaa aacagccctg tcacacctgt tggagccagc aaaacagcac tgcgaatttc

```

Fig. 3 D (continued):

```

2761 acagagcact ttttaataacc cagcaccagg gcaactgggc aggttattgc caaaccagaa
2821 tttaccactt gacatcacat tgcaaaagccc aactggtgct ggacctttcc caccaatcag
2881 aaacagtagt ccctactcag tgatacctca gccagggaatg atgggtaatc aagggatgat
2941 aggaaaccaa ggaatttttag ggaacagtag cacagggaatg attggtaaca gtgcttctcg
3001 gcctactatg ccatctggag aatgggcacc gcagagttcg gctgtgagag tcacctgtgc
3061 tgctaccacc agtgccatga accggccagt ccaaggaggt atgattcggg acccagcagc
3121 cagcatcccc atgaggccca gcagccagcc tggccaaaga cagacgcttc agtctcaggt
3181 catgaatata gggccatctg aattagagat gaacatgggg ggacctcagt atagccaaca
3241 acaagctcct ccaaatcaga ctgccccatg gcctgaaagc atcctgccta tagaccaggc
3301 gtcttttgcc agccaaaaca ggcagccatt tggcagttct ccagatgact tgctatgtcc
3361 acatcctgca gctgagtcct cgagtgatga gggagctctc ctggaccagc tgatctctggc
3421 cttgcggaat ttgatggcc tggaggagat tgatagagcc ttaggaaatc ccgaactggt
3481 cagccagagc caagcagtag atccagaaca gttctcaagt caggattcca acatcatgct
3541 ggagcagaag gcgcccgttt tcccacagca gtatgcatct caggcacaaa tggccccaggg
3601 tagctattct cccatgcaag atccaaactt tcacaccatg ggacagcggc ctagtattgc
3661 cacactccgt atgcagccca gaccgggcct caggcccacg ggcctagtgc agaaccagcc
3721 aaatcaacta agacttcaac ttccagcatcg cctccaagca cagcagaatc gccagccact
3781 tatgaatcaa atcagcaatg ttccaatgt gaacttgact ctgaggcctg gagtaccaac
3841 acaggcacct attaatgcac agatgctggc ccagagacag agggaaatcc tgaaccagca
3901 tcttcgacag agacaaatgc atcagcaaca gcaagttcag caacgaactt tgatgatgag
3961 aggacaaggg ttgaatatga caccaagcat ggtggctcct agtggtagc cagcaactat
4021 gagcaacctt cggattcccc agggcaaatgc acagcagttt ccatttcctc caaactacgg
4081 aataagtcag caacctgato caggctttac tggggctacg actccccaga gcccaacttat
4141 gtcacccaga atggcacata cacagagtcct catgatgcaa cagtctcagg ccaaccagc
4201 ctatcagccc cctccgaca taaatggatg ggcgagggg aacatggcg gaaacagcat
4261 gttttcccag cagtcaccac cacactttgg gcagcaagca aacaccagca tgtacagtaa
4321 caacatgaac atcaatgtgt ccatggcgac caacacaggt ggcattgagca gcatgaacca
4381 gatgacagga cagatcagca tgacctcagt gacctccgtg cctacgtcag ggctgtcctc
4441 catgggtccc gagcaggtta atgacctgtc tctgagggga ggcaacctgt tcccaccca
4501 gctgcctgga atggatatga ttaagcagga gggagacaca acacggaaat attgctgaca
4561 ctgctgaagc cagttgcttc ttccagctgac cgggctcact tgctcaaac acttccagtc
4621 tggagagctg tgtctatttg tttcaaccca actgacctgc cagccggttc tgctagagca
4681 gacagggctg gccctgggtc ccagggtggc gtccactcgg ctgtggcagg aggagctgcc
4741 tcttctcttg acagtctgaa gctcgcatcc agacagtcgc tcagtctgtt cactgcattc
4801 accttagtgc aacttagatc tctcctgcaa aagtaaagt tgacaggcaa atttcatacc
4861 catgtcagat tgaatgtatt taaatgtatg tatttaagga gaacctagct cttgttctgt
4921 tcctgttcgg ttccagacac tgggttcttg ctttgtttcc cctggctaac agtctagtgc
4981 aaaagattaa gattttatct ggggaaaaga aaagaatttt ttaaaaaatt aaactaaaga
5041 tgttttaagc taaagcctga atttgggatg gaagcaggac agacaccgtg gacagcgctg
5101 tatttacaga cacacccagt gcgtgaagac caacaaagtc acagtcgtat ctctagaaag
5161 ctctaaagac catgttgaa agagtctcca gttactgaac agatgaaaag gagcctgtga
5221 gagggctgtt aacattagca aatatttttt ccttgttttt tctttgttaa aaccacactg
5281 gttcacctga atcatgaatt gagaagaaat aattttcatt tctaataata gtccctttta
5341 gtttgatcag acagcttgaa tcagcatctc ttcttccctg tcagcctgac tcttcccttc
5401 cctctctca ttccccatcc tccctatttt cattcctttt ttaaaaaata atataagcta
5461 cagaaaccag gtaagccctt tatttcctta aatgttttgc cagccactta ccaattgtca
5521 agtattgaat ttcagaaaaa aaaaatgcat ttactggcaa ggagaagagc aaagttaagg
5581 cttgatacca atcgagctaa ggatacctgc tttggaagca tgtttattct gttccccagc
5641 aactctggcc tccaaaatgg gagaaaacgc cagtgtgttt aaattgatag cagatatcac
5701 gacagattta acctctgcca tgtgtttttt atttgtttt tttagcagtc tgactaagcc
5761 gaagttttgt aaggtacata aaatccaatt tatatgtaaa caagcaataa ttttaagtga
5821 gaacttatgt gttttaattg tataattttt gtgaggtata catattgtgg aattgactca
5881 aaaatgaggt acttcagtat taaattagat atcttcatag caatgtctcc taaagggtgt
5941 ttgtaaagga tatcaatgcc ttgattagac ctaatttgta gacttaagac tttttatatt
6001 ctaaaccttg tgattctgct tataagtcat ttatctaate tatatgatat gcagccgctg
6061 taggaacca ttcttgattt ttatatgttt atattccttc ttaatgaacc ttagaaagac
6121 tacatgttac taagcaggcc acttttatgt ttgttttt

```

Fig. 3 E:

```

1  MSSPTTSSLD  TPLPGNGPPQ  PGAPSSSPTV  KEEGPEPWPG  GPDPDVPGTD  EASSACSTDW
61  VIPDPEEEPE  RKRKKGPAPK  MLGHELCRVC  GDKASGFHYN  VLSCEGCKGF  FRRSVVRGGA
121 RRYACRGGGT  CQMDAFMRK  CQQCRLRKCK  EAGMREQCVL  SEEQIRKKKI  RKQQQESQSQ
181 SQSPVGPGS  SSSASGPGAS  PGGSEAGSQG  SGEGEGVOLT  AAQELMIQQL  VAAQLQCNKR
241 SFSDQPKVTP  WPLGADPQSR  DARQQRFAHF  TELAIISVQE  IVDFAKQVPG  FLQLGREDQI
301 ALLKASTIEI  MLEETARRYN  HETECITFLK  DFTYSKDDFH  RAGLQVEFIN  PIFEFSTRAMR
361 RLGLDDAEYA  LLIAINIFSA  DRPNVQEPGR  VEALQQPYVE  ALLSYTRIKR  PQDQLRFPRM
421 LMKLVSLRTL  SSVHSEQVFA  LRLQDKKLPP  LLSEIWDVHE

```






Fig. 3 F:

```

1  atgtcctctc  ctaccacgag  ttccctggat  acccccctgc  ctggaaatgg  cccccctcag
61  cctggcgccc  cttcttcttc  acccactgta  aaggaggagg  gtccggagcc  gtggcccggg
121 ggtccggacc  ctgatgtccc  aggcactgat  gaggccagct  cagcctgcag  cacagactgg
181 gtcatcccag  atcccgaaga  ggaaccagag  cgcaagcgaa  agaagggccc  agccccgaag
241 atgctgggcc  acgagctttg  ccgtgtctgt  ggggacaagg  cctccggctt  ccactacaac
301 gtgtcagct  gcgaaggctg  caagggcttc  ttccggcgca  gtgtggtccg  tggtagggcc
361 aggcgctatg  cctgccgggg  tggcggaacc  tgccagatgg  acgctttcat  gcggcgcaag
421 tgccagcagt  gccggctcgc  caagtgaag  gaggcaggga  tgagggagca  gtgcgtcctt
481 tctgaagaac  agatccgga  gaagaagatt  cggaacagc  agcaggagtc  acagtccag
541 tcgcagtcac  ctgtggggcc  gcagggcagc  agcagctcag  cctctgggcc  tggggcttcc
601 cctggtggat  ctgaggcagg  cagccagggc  tccggggaag  gcgaggggtg  ccagctaaca
661 gcggctcaag  aactaatgat  ccagcagttg  gtggcgggcc  aactgcagtg  caacaaacgc
721 tccttctccg  accagcccaa  agtcacgccc  tggcccctgg  gcgcagaccc  ccagtccga
781 gatgcccgcc  agcaacgctt  tgcccacttc  acggagctgg  ccatcatctc  agtccaggag
841 atcgtggact  tcgctaagca  agtgcctggt  ttcttgacgc  tgggcccggg  ggaccagatc
901 gccctcctga  aggcattcac  tatcgagatc  atgctgctag  agacagccag  gcgctacaac
961 cagagacag  agtgtatcac  cttcttgaag  gacttcacct  acagcaagga  cgacttcac
1021 cgtgcaggcc  tgcagggtga  gttcatcaac  cccatcttcg  agttctcgcg  ggccatgcgg
1081 cggctgggcc  tggacgacgc  tgagtacgcc  ctgctcatcg  ccatcaacat  cttctcgcc
1141 gaccggccca  acgtgcagga  gccgggccgc  gtggaggcgt  tgcagcagcc  ctacgtggag
1201 gcgctgctgt  cctacacgcg  catcaagagg  ccgcaggacc  agctgcgctt  cccgcgcatg
1261 ctcatgaagc  tggtagagcct  gcgcacgctg  agctctgtgc  actcggagca  ggtcttcgcc
1321 ttgcggctcc  aggacaagaa  gctgccgcct  ctgctgtcgg  agatctggga  cgtccacgag
1381 tga

```

Fig. 4 A:

| MOLNAME | MOLECULE STRUCTURE | EC50 AVG | EFFIC AVG |
|--------------|---|----------|-----------|
| LN0000003252 |  | 0.59 | 110 |
| LN0000007459 |  | 0.12 | 129 |
| LN0000011283 |  | 0.18 | 137 |
| TR1040007465 |  | 1.2 | 114 |
| LN0000007460 |  | 2,6 | 111 |
| LN0000006500 | | 0,34 | 133 |



| | | | |
|--------------|---|------|-----|
| |  | | |
| LN0000006494 |  | 0,23 | 112 |

Fig. 4 A (cont.)





| MOLNAME | MOLECULE STRUCTURE | EC50 AVG | EFFIC AVG |
|--------------|---|----------|-----------|
| LN0000007364 |  | 1.5 | 101 |
| LN0000003492 |  | 0.11 | 115 |
| LN0000007180 |  | 0.15 | 128 |
| LN0000007179 |  | 0.78 | 127 |

Fig. 4 A (cont.):

10/16

Fig. 5:





Fig. 6


Liver X receptor alpha, LXR α (NM_005693)
Cholesterol 7 α hydroxylase, Cyp7A1 (NM_000780)
FAS (NM_004104)
Stearyl CoA desaturase, SCD (XM_030447)
Sterol Response Element Binding Protein 1C, SREBP-1C (NM_004176)
ATP binding cassette transporter A1; ABCA1 (NM_005502)
ATP binding cassette transporter G1; ABCG1 (XM_032950)
ATP binding cassette transporter A1; ABCG5 (NM_031884)
ATP binding cassette transporter A1; ABCG8 AF324494
Apolipoprotein E, apoE (NM_000041)
Apolipoprotein C-I, apoC-I (NM_001645)
Apolipoprotein C-II apoC-II (NM_000483)
Apolipoprotein C-IV, apoC-IV (U32576)
Lipoprotein Lipase, LPL (M15856)
Cholesteryl Ester Transfer Protein, CETP (NM_000078)

Fig. 7:




Best Available Copy

Fig. 8A:



Best Available Copy

Fig. 8B



Best Available Copy

Fig. 9





Fig. 10:



SEQUENCE LISTING

<110> LION bioscience
<120> LXR Nuclear receptor binding compounds
<130> L30281PCT
<160> 8
<170> PatentIn version 3.1

<210> 1
<211> 52
<212> DNA
<213> Homo sapiens

<400> 1
ggggaccact ttgtacaaga aagctgggtc cccttctcag tctgttccac tt 52

<210> 2
<211> 1344
<212> DNA
<213> Homo sapiens

<400> 2
atgtccttgt ggctgggggc ccctgtgcct gacattcctc ctgactctgc ggtggagctg 60
tggaagccag ggcacagga tgcaagcagc caggcccagg gaggcagcag ctgcatcctc 120
agagaggaag ccaggatgcc cactctgtct gggggtactg caggggtggg gctggaggct 180
gcagagccca cagccctgct caccagggca gagccccctt cagaaccac agagatccgt 240
ccacaaaagc ggaaaaaggg gccagcccc aaaatgctgg ggaacgagct atgcagcgtg 300
tgtggggaca aggcctcggg cttccactac aatgttctga gctgcgaggg ctgcaaggga 360
ttcttccgcc gcagcgtcat caaggagcg cactacatct gccacagtgg cggccactgc 420
cccatggaca cctacatgcg tcgcaagtgc caggagtgtc ggcttcgcaa atgccgtcag 480
gctggcatgc gggaggagtg tgtcctgtca gaagaacaga tccgcctgaa gaaactgaag 540
cggcaagagg aggaacaggc tcatgccaca tccttgcccc ccaggcggtc ctcaccccc 600
caaatcctgc ccagctcag ccggaacaa ctgggcatga tcgagaagct cgtcgctgcc 660
cagcaacagt gtaaccggcg ctcttttct gaccggcttc ggtcacgcc ttggcccatg 720
gcaccagatc cccatagccg ggaggcccg cagcagcgt ttgcccactt cactgagctg 780
gccatcgtct ctgtgcagga gatagttgac tttgctaaac agctaccgg cttcctgcag 840
ctcagccggg aggaccagat tgccctgctg aagacctctg cgatcgaggt gatgcttctg 900
gagacatctc ggaggtacaa ccctgggagt gagagtatca ccttctcaa ggatttcagt 960
tataaccggg aagactttgc caaagcaggg ctgcaagtgg aattcatcaa cccatcttc 1020
gagttctcca gggccatgaa tgagctgcaa ctcaatgatg ccgagtttgc cttgctcatt 1080
gctatcagca tcttctctgc agaccggccc aacgtgcagg accagctcca ggtggagagg 1140
ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac 1200

cgactgatgt tcccacggat gctaataaaa ctggtgagcc tccggaccct gagcagcgctc 1260
 cactcagagc aagtgtttgc actgcgtctg caggacaaaa agctcccacc gctgctctct 1320
 gagatctggg atgtgcacga atga 1344

<210> 3
 <211> 1263
 <212> PRT
 <213> Homo sapiens
 <400> 3

Met Leu Val Lys Pro Leu Pro Asp Ser Glu Glu Glu Gly His Asp Asn
 1 5 10 15

Gln Glu Ala His Gln Lys Tyr Glu Thr Met Gln Cys Phe Ala Val Ser
 20 25 30

Gln Pro Lys Ser Ile Lys Glu Glu Gly Glu Asp Leu Gln Ser Cys Leu
 35 40 45

Ile Cys Val Ala Arg Arg Val Pro Met Lys Glu Arg Pro Val Leu Pro
 50 55 60

Ser Ser Glu Ser Phe Thr Thr Arg Gln Asp Leu Gln Gly Lys Ile Thr
 65 70 75 80

Ser Leu Asp Thr Ser Thr Met Arg Ala Ala Met Lys Pro Gly Trp Glu
 85 90 95

Asp Leu Val Arg Arg Cys Ile Gln Lys Phe His Ala Gln His Glu Gly
 100 105 110

Glu Ser Val Ser Tyr Ala Lys Arg His His His Glu Val Leu Arg Gln
 115 120 125

Gly Leu Ala Phe Ser Gln Ile Tyr Arg Phe Ser Leu Ser Asp Gly Thr
 130 135 140

Leu Val Ala Ala Gln Thr Lys Ser Lys Leu Ile Arg Ser Gln Thr Thr
 145 150 155 160

Asn Glu Pro Gln Leu Val Ile Ser Leu His Met Leu His Arg Glu Gln
 165 170 175

Asn Val Cys Val Met Asn Pro Asp Leu Thr Gly Gln Thr Met Gly Lys
 180 185 190

Pro Leu Asn Pro Ile Ser Ser Asn Ser Pro Ala His Gln Ala Leu Cys
 195 200 205

Ser Gly Asn Pro Gly Gln Asp Met Thr Leu Ser Ser Asn Ile Asn Phe
 210 215 220

Pro Ile Asn Gly Pro Lys Glu Gln Met Gly Met Pro Met Gly Arg Phe
 225 230 235 240

Gly Gly Ser Gly Gly Met Asn His Val Ser Gly Met Gln Ala Thr Thr
 245 250 255

Pro Gln Gly Ser Asn Tyr Ala Leu Lys Met Asn Ser Pro Ser Gln Ser
 260 265 270

Ser Pro Gly Met Asn Pro Gly Gln Pro Thr Ser Met Leu Ser Pro Arg
 275 280 285

His Arg Met Ser Pro Gly Val Ala Gly Ser Pro Arg Ile Pro Pro Ser
 290 295 300

Gln Phe Ser Pro Ala Gly Ser Leu His Ser Pro Val Gly Val Cys Ser
 305 310 315 320

Ser Thr Gly Asn Ser His Ser Tyr Thr Asn Ser Ser Leu Asn Ala Leu
 325 330 335

Gln Ala Leu Ser Glu Gly His Gly Val Ser Leu Gly Ser Ser Leu Ala
 340 345 350

Ser Pro Asp Leu Lys Met Gly Asn Leu Gln Asn Ser Pro Val Asn Met
 355 360 365

Asn Pro Pro Pro Leu Ser Lys Met Gly Ser Leu Asp Ser Lys Asp Cys
 370 375 380

Phe Gly Leu Tyr Gly Glu Pro Ser Glu Gly Thr Thr Gly Gln Ala Glu
 385 390 395 400

Ser Ser Cys His Pro Gly Glu Gln Lys Glu Thr Asn Asp Pro Asn Leu
 405 410 415

Pro Pro Ala Val Ser Ser Glu Arg Ala Asp Gly Gln Ser Arg Leu His
 420 425 430

Asp Ser Lys Gly Gln Thr Lys Leu Leu Gln Leu Leu Thr Thr Lys Ser
 435 440 445

Asp Gln Met Glu Pro Ser Pro Leu Ala Ser Ser Leu Ser Asp Thr Asn

450 455 460
 Lys Asp Ser Thr Gly Ser Leu Pro Gly Ser Gly Ser Thr His Gly Thr
 465 470 475 480
 Ser Leu Lys Glu Lys His Lys Ile Leu His Arg Leu Leu Gln Asp Ser
 485 490 495
 Ser Ser Pro Val Asp Leu Ala Lys Leu Thr Ala Glu Ala Thr Gly Lys
 500 505 510
 Asp Leu Ser Gln Glu Ser Ser Ser Thr Ala Pro Gly Ser Glu Val Thr
 515 520 525
 Ile Lys Gln Glu Pro Val Ser Pro Lys Lys Lys Glu Asn Ala Leu Leu
 530 535 540
 Arg Tyr Leu Leu Asp Lys Asp Asp Thr Lys Asp Ile Gly Leu Pro Glu
 545 550 555 560
 Ile Thr Pro Lys Leu Glu Arg Leu Asp Ser Lys Thr Asp Pro Ala Ser
 565 570 575
 Asn Thr Lys Leu Ile Ala Met Lys Thr Glu Lys Glu Glu Met Ser Phe
 580 585 590
 Glu Pro Gly Asp Gln Pro Gly Ser Glu Leu Asp Asn Leu Glu Glu Ile
 595 600 605
 Leu Asp Asp Leu Gln Asn Ser Gln Leu Pro Gln Leu Phe Pro Asp Thr
 610 615 620
 Arg Pro Gly Ala Pro Ala Gly Ser Val Asp Lys Gln Ala Ile Ile Asn
 625 630 635 640
 Asp Leu Met Gln Leu Thr Ala Glu Asn Ser Pro Val Thr Pro Val Gly
 645 650 655
 Ala Gln Lys Thr Ala Leu Arg Ile Ser Gln Ser Thr Phe Asn Asn Pro
 660 665 670
 Arg Pro Gly Gln Leu Gly Arg Leu Leu Pro Asn Gln Asn Leu Pro Leu
 675 680 685
 Asp Ile Thr Leu Gln Ser Pro Thr Gly Ala Gly Pro Phe Pro Pro Ile
 690 695 700

Arg Asn Ser Ser Pro Tyr Ser Val Ile Pro Gln Pro Gly Met Met Gly
 705 710 715 720

Asn Gln Gly Met Ile Gly Asn Gln Gly Asn Leu Gly Asn Ser Ser Thr
 725 730 735

Gly Met Ile Gly Asn Ser Ala Ser Arg Pro Thr Met Pro Ser Gly Glu
 740 745 750

Trp Ala Pro Gln Ser Ser Ala Val Arg Val Thr Cys Ala Ala Thr Thr
 755 760 765

Ser Ala Met Asn Arg Pro Val Gln Gly Gly Met Ile Arg Asn Pro Ala
 770 775 780

Ala Ser Ile Pro Met Arg Pro Ser Ser Gln Pro Gly Gln Arg Gln Thr
 785 790 795 800

Leu Gln Ser Gln Val Met Asn Ile Gly Pro Ser Glu Leu Glu Met Asn
 805 810 815

Met Gly Gly Pro Gln Tyr Ser Gln Gln Gln Ala Pro Pro Asn Gln Thr
 820 825 830

Ala Pro Trp Pro Glu Ser Ile Leu Pro Ile Asp Gln Ala Ser Phe Ala
 835 840 845

Ser Gln Asn Arg Gln Pro Phe Gly Ser Ser Pro Asp Asp Leu Leu Cys
 850 855 860

Pro His Pro Ala Ala Glu Ser Pro Ser Asp Glu Gly Ala Leu Leu Asp
 865 870 875 880

Gln Leu Tyr Leu Ala Leu Arg Asn Phe Asp Gly Leu Glu Glu Ile Asp
 885 890 895

Arg Ala Leu Gly Ile Pro Glu Leu Val Ser Gln Ser Gln Ala Val Asp
 900 905 910

Pro Glu Gln Phe Ser Ser Gln Asp Ser Asn Ile Met Leu Glu Gln Lys
 915 920 925

Ala Pro Val Phe Pro Gln Gln Tyr Ala Ser Gln Ala Gln Met Ala Gln
 930 935 940

Gly Ser Tyr Ser Pro Met Gln Asp Pro Asn Phe His Thr Met Gly Gln
 945 950 955 960

Arg Pro Ser Tyr Ala Thr Leu Arg Met Gln Pro Arg Pro Gly Leu Arg
 965 970 975

Pro Thr Gly Leu Val Gln Asn Gln Pro Asn Gln Leu Arg Leu Gln Leu
 980 985 990

Gln His Arg Leu Gln Ala Gln Gln Asn Arg Gln Pro Leu Met Asn Gln
 995 1000 1005

Ile Ser Asn Val Ser Asn Val Asn Leu Thr Leu Arg Pro Gly Val
 1010 1015 1020

Pro Thr Gln Ala Pro Ile Asn Ala Gln Met Leu Ala Gln Arg Gln
 1025 1030 1035

Arg Glu Ile Leu Asn Gln His Leu Arg Gln Arg Gln Met His Gln
 1040 1045 1050

Gln Gln Gln Val Gln Gln Arg Thr Leu Met Met Arg Gly Gln Gly
 1055 1060 1065

Leu Asn Met Thr Pro Ser Met Val Ala Pro Ser Gly Met Pro Ala
 1070 1075 1080

Thr Met Ser Asn Pro Arg Ile Pro Gln Ala Asn Ala Gln Gln Phe
 1085 1090 1095

Pro Phe Pro Pro Asn Tyr Gly Ile Ser Gln Gln Pro Asp Pro Gly
 1100 1105 1110

Phe Thr Gly Ala Thr Thr Pro Gln Ser Pro Leu Met Ser Pro Arg
 1115 1120 1125

Met Ala His Thr Gln Ser Pro Met Met Gln Gln Ser Gln Ala Asn
 1130 1135 1140

Pro Ala Tyr Gln Ala Pro Ser Asp Ile Asn Gly Trp Ala Gln Gly
 1145 1150 1155

Asn Met Gly Gly Asn Ser Met Phe Ser Gln Gln Ser Pro Pro His
 1160 1165 1170

Phe Gly Gln Gln Ala Asn Thr Ser Met Tyr Ser Asn Asn Met Asn
 1175 1180 1185

Ile Asn Val Ser Met Ala Thr Asn Thr Gly Gly Met Ser Ser Met
 1190 1195 1200

Asn Gln Met Thr Gly Gln Ile Ser Met Thr Ser Val Thr Ser Val
1205 1210 1215

Pro Thr Ser Gly Leu Ser Ser Met Gly Pro Glu Gln Val Asn Asp
1220 1225 1230

Pro Ala Leu Arg Gly Gly Asn Leu Phe Pro Asn Gln Leu Pro Gly
1235 1240 1245

Met Asp Met Ile Lys Gln Glu Gly Asp Thr Thr Arg Lys Tyr Cys
1250 1255 1260

<210> 4
<211> 6158
<212> DNA
<213> Homo sapiens

<400> 4
ggcgcccgca gcctcggtta cagcttcggc ggcgaaggctc agcgccgacg gcagccggca 60
cctgacggcg tgaccgaccc gagccgattt ctcttggtt tggctacaca cttatagatc 120
ttctgcactg tttacaggca cagttgctga tatgtgttca agatgagtgg gatgggagaa 180
aatacctctg acccctccag ggcagagaca agaaagcgca agaatgtcc tgaccaactt 240
ggaccagcc ccaaaaggaa cactgaaaaa cgtaatcgtg aacaggaaaa taaatatata 300
gaagaacttg cagagttgat ttttgcaaat tttaatgata tagacaactt taacttcaaa 360
cctgacaaat gtgcaatctt aaaagaaact gtgaagcaaa ttcgtcagat caaagaacaa 420
gagaaagcag cagctgccaa catagatgaa gtgcagaagt cagatgtatc ctctacaggg 480
cagggtgtca tcgacaagga tgcgctgggg cctatgatgc ttgaggccct tgatgggttc 540
ttctttgtag tgaacctgga aggcaacgtt gtgtttgtgt cagagaatgt gacacagtat 600
ctaaggata accaagaaga gctgatgaac aaaagtgtat atagcatctt gcatgttggg 660
gaccacacgg aatttgtcaa aaacctgctg ccaaagtcta taggtaaatg ggggatcttg 720
gtctggcgaa cctccgaggc ggaacagcca taccttcaat tgcggatgc tggtaaaacc 780
tttacctgat tcagaagagg agggatcatga taaccaggaa gctcatcaga aatatgaaac 840
tatgcagtgc ttcgctgtct ctcaaccaa gtccatcaaa gaagaaggag aagatttgca 900
gtcctgcttg atttgctgg caagaagagt tccatgaag gaaagaccag ttcttcctc 960
atcagaaagt ttactactc gccaggatct ccaaggcaag atcacgtctc tggataccag 1020
caccatgaga gcagccatga aaccaggctg ggaggacctg gtaagaaggt gtattcagaa 1080
gttccatgcg cagcatgaag gagaatctgt gtcctatgct aagaggcatc atcatgaagt 1140
actgagacaa ggattggcat tcagtcaaat ctatcgtttt tcttgtctg atggcactct 1200

| | |
|---|------|
| tggtgctgca caaacgaaga gcaaactcat ccgttctcag actactaatg aacctcaact | 1260 |
| tgtaatatct ttacatatgc ttcacagaga gcagaatgtg tgtgtgatga atccggatct | 1320 |
| gactggacaa acgatgggga agccactgaa tccaattagc tctaacagcc ctgcccacatca | 1380 |
| ggccctgtgc agtgggaacc caggtcagga catgaccctc agtagcaata taaattttcc | 1440 |
| cataaatggc ccaaaggaac aaatgggcat gcccatgggc aggttttgtg gttctggggg | 1500 |
| aatgaaccat gtgtcaggca tgcaagcaac cactcctcag ggtagtaact atgcactcaa | 1560 |
| aatgaacagc ccctcacaaa gcagccctgg catgaatcca ggacagccca cctccatgct | 1620 |
| ttcaccaagg catcgcatga gccctggagt ggctggcagc cctcgaatcc caccagtcac | 1680 |
| gttttcccct gcaggaagct tgcattcccc tgtgggagtt tgcagcagca caggaaatag | 1740 |
| ccatagttat accaacagct ccctcaatgc acttcaggcc ctcagcgagg ggcacggggg | 1800 |
| ctcattaggg tcatcggttg cttcaccaga cctaaaaatg ggcaatttgc aaaactcccc | 1860 |
| agttaatatg aatcctcccc cactcagcaa gatgggaagc ttggactcaa aagactgttt | 1920 |
| tggactatat ggggagccct ctgaaggtag aactggacaa gcagagagca gctgccatcc | 1980 |
| tggagagcaa aaggaaacaa atgaccccaa cctgcccccg gccgtgagca gtgagagagc | 2040 |
| tgacgggcag agcagactgc atgacagcaa agggcagacc aaactcctgc agctgctgac | 2100 |
| caccaaactct gatcagatgg agccctcgcc cttagccagc tctttgtcgg atacaaacaa | 2160 |
| agactccaca ggtagcttgc ctggttctgg gtctacacat ggaacctgc tcaaggagaa | 2220 |
| gcataaaatt ttgcacagac tcttgacagga cagcagttcc cctgtggact tggccaagtt | 2280 |
| aacagcagaa gccacaggca aagacctgag ccaggagtcc agcagcacag ctcctggatc | 2340 |
| agaagtgact attaaacaag agccggtgag cccaagaag aaagagaatg cactacttcg | 2400 |
| ctatttgcta gataaagatg atactaaaga tattggttta ccagaaataa ccccaaact | 2460 |
| tgagagactg gacagtaaga cagatcctgc cagtaacaca aaattaatag caatgaaaac | 2520 |
| tgagaaggag gagatgagct ttgagcctgg tgaccagcct ggcagtgagc tggacaactt | 2580 |
| ggaggagatt ttggatgatt tgcagaatag tcaattacca cagcttttcc cagacacgag | 2640 |
| gccaggcgcc cctgctggat cagttgacaa gcaagccatc atcaatgacc tcatgcaact | 2700 |
| cacagctgaa aacagccctg tcacacctgt tggagcccag aaaacagcac tgcgaatttc | 2760 |
| acagagcact ttaataaacc cacgaccagg gcaactgggc aggttattgc caaaccagaa | 2820 |
| tttaccactt gacatcacat tgcaaagccc aactggtgct ggacctttcc caccaatcag | 2880 |
| aaacagtagt ccctactcag tgatacctca gccaggaatg atgggtaatc aagggatgat | 2940 |
| aggaaaccaa ggaaatttag ggaacagtag cacaggaatg attggttaaca gtgcttctcg | 3000 |
| gcctactatg ccatctggag aatgggcacc gcagagttcg gctgtgagag tcacctgtgc | 3060 |

tgctaccacc agtgccatga accggccagt ccaaggaggt atgattcgga acccagcagc 3120
cagcatcccc atgaggccca gcagccagcc tggccaaaga cagacgcttc agtctcaggt 3180
catgaatata gggccatctg aattagagat gaacatgggg ggacctcagt atagccaaca 3240
acaagctcct ccaaatacaga ctgccccatg gcctgaaagc atcctgccta tagaccaggc 3300
gtcttttgcc agccaaaaca ggcagccatt tggcagttct ccagatgact tgctatgtcc 3360
acatcctgca gctgagtctc cgagtgatga gggagctctc ctggaccagc tgtatctggc 3420
cttgcggaat tttgatggcc tggaggagat tgatagagcc ttaggaatac ccgaactggg 3480
cagccagagc caagcagtag atccagaaca gttctcaagt caggattcca acatcatgct 3540
ggagcagaag gcgcccgttt tcccacagca gtatgcatct caggcacaaa tggcccaggg 3600
tagctattct cccatgcaag atccaaactt tcacaccatg ggacagcggc ctagttatgc 3660
cacactccgt atgcagccca gaccgggcct caggcccacg ggcttagtgc agaaccagcc 3720
aatcaacta agacttcaac ttcagcatcg cctccaagca cagcagaatc gccagccact 3780
tatgaatcaa atcagcaatg tttccaatgt gaacttgact ctgaggcctg gagtaccaac 3840
acaggcacct attaatgcac agatgctggc ccagagacag agggaaatcc tgaaccagca 3900
tcttcgacag agacaaatgc atcagcaaca gcaagttcag caacgaactt tgatgatgag 3960
aggacaaggg ttgaatatga caccaagcat ggtggctcct agtgggtatgc cagcaactat 4020
gagcaaccct cggattcccc aggcaaatgc acagcagttt ccatttcctc caaactacgg 4080
aataagtcag caacctgatc caggctttac tggggctacg actccccaga gccacttat 4140
gtcaccccgga atggcacata cacagagtcc catgatgcaa cagtctcagg ccaaccagc 4200
ctatcaggcc ccctccgaca taaatggatg ggcgagggg aacatgggag gaaacagcat 4260
gttttcccag cagtccccac cacactttgg gcagcaagca aacaccagca tgtacagtaa 4320
caacatgaac atcaatgtgt ccatggcgac caacacaggt ggcatgagca gcatgaacca 4380
gatgacagga cagatcagca tgacctcagt gacctccgtg cctacgtcag ggctgtcctc 4440
catgggtccc gagcagggtta atgatcctgc tctgagggga ggcaacctgt tcccaaacca 4500
gctgcctgga atggatatga ttaagcagga gggagacaca acacggaaat attgctgaca 4560
ctgtgaagc cagttgcttc ttcagctgac cgggctcact tgcacaaaac acttcagtc 4620
tggagagctg tgtctatttg tttcaacca actgacctgc cagccggttc tgctagagca 4680
gacaggcctg gccctgggtc ccagggtggc gtccactcgg ctgtggcagg aggagctgcc 4740
tcttctcttg acagtctgaa gctcgcatcc agacagtcgc tcagtctgtt cactgcattc 4800
accttagtgc aacttagatc tctcctgcaa aagtaaagt tgacaggcaa atttcatacc 4860
catgtcagat tgaatgtatt taaatgtatg tatttaagga gaaccatgct cttgttctgt 4920
tcctgttcgg ttccagacac tggtttcttg ctttgttttc cctggctaac agtctagtgc 4980

```

aaaagattaa gattttatct gggggaaaga aaagaatttt ttaaaaaatt aaactaaaga 5040
tgttttaagc taaagcctga atttgggatg gaagcaggac agacaccgtg gacagcgctg 5100
tatttacaga cacacccagt gcgtgaagac caacaaagtc acagtcgtat ctctagaaag 5160
ctctaaagac catgttgga agagtctcca gttactgaac agatgaaaag gagcctgtga 5220
gagggtgtt aacattagca aatatttttt ccttggtttt tctttgttaa aaccaaactg 5280
gttcacctga atcatgaatt gagaagaaat aattttcatt tctaaattaa gtccctttta 5340
gttgatcag acagcttgaa tcagcatctc ttcttccttg tcagcctgac tcttccttc 5400
ccctctctca ttcccatac tccctatttt cattcctttt ttaaaaaata atataagcta 5460
cagaaaccag gtaagccctt tatttcctta aatgttttgc cagccactta ccaattgcta 5520
agtattgaat ttcagaaaaa aaaaatgcat ttactggcaa ggagaagagc aaagttaagg 5580
cttgatacca atogagctaa ggatacctgc tttggaagca tgtttattct gttcccagc 5640
aactctggcc tccaaaatgg gagaaaacgc cagtgtgttt aaattgatag cagatatcac 5700
gacagattta acctctgcca tgtgtttttt attttgtttt ttagcagtgc tgactaagcc 5760
gaagttttgt aaggtacata aaatccaatt tatatgtaaa caagcaataa ttttaagttga 5820
gaacttatgt gttttaattg tataattttt gtgaggtata catattgtgg aattgactca 5880
aaaatgaggt acttcagtat taaattagat atcttcatag caatgtctcc taaaggtgtt 5940
ttgtaaagga tatcaatgcc ttgattagac ctaatttgta gacttaagac tttttatttt 6000
ctaaaccttg tgattctgct tataagtcac ttatctaate tatatgatat gcagccgctg 6060
taggaaccaa ttcttgattt ttatatgttt atattctttc ttaatgaacc ttagaaagac 6120
tacaatgttac taagcaggcc acttttatgg ttgttttt 6158

```

```

<210> 5
<211> 460
<212> PRT
<213> Homo sapiens
<400> 5

```

```

Met Ser Ser Pro Thr Thr Ser Ser Leu Asp Thr Pro Leu Pro Gly Asn
1          5          10          15

```

```

Gly Pro Pro Gln Pro Gly Ala Pro Ser Ser Ser Pro Thr Val Lys Glu
20          25          30

```

```

Glu Gly Pro Glu Pro Trp Pro Gly Gly Pro Asp Pro Asp Val Pro Gly
35          40          45

```

```

Thr Asp Glu Ala Ser Ser Ala Cys Ser Thr Asp Trp Val Ile Pro Asp
50          55          60

```

Pro Glu Glu Glu Pro Glu Arg Lys Arg Lys Lys Gly Pro Ala Pro Lys
 65 70 75 80

Met Leu Gly His Glu Leu Cys Arg Val Cys Gly Asp Lys Ala Ser Gly
 85 90 95

Phe His Tyr Asn Val Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg
 100 105 110

Arg Ser Val Val Arg Gly Gly Ala Arg Arg Tyr Ala Cys Arg Gly Gly
 115 120 125

Gly Thr Cys Gln Met Asp Ala Phe Met Arg Arg Lys Cys Gln Gln Cys
 130 135 140

Arg Leu Arg Lys Cys Lys Glu Ala Gly Met Arg Glu Gln Cys Val Leu
 145 150 155 160

Ser Glu Glu Gln Ile Arg Lys Lys Lys Ile Arg Lys Gln Gln Gln Glu
 165 170 175

Ser Gln Ser Gln Ser Gln Ser Pro Val Gly Pro Gln Gly Ser Ser Ser
 180 185 190

Ser Ala Ser Gly Pro Gly Ala Ser Pro Gly Gly Ser Glu Ala Gly Ser
 195 200 205

Gln Gly Ser Gly Glu Gly Glu Gly Val Gln Leu Thr Ala Ala Gln Glu
 210 215 220

Leu Met Ile Gln Gln Leu Val Ala Ala Gln Leu Gln Cys Asn Lys Arg
 225 230 235 240

Ser Phe Ser Asp Gln Pro Lys Val Thr Pro Trp Pro Leu Gly Ala Asp
 245 250 255

Pro Gln Ser Arg Asp Ala Arg Gln Gln Arg Phe Ala His Phe Thr Glu
 260 265 270

Leu Ala Ile Ile Ser Val Gln Glu Ile Val Asp Phe Ala Lys Gln Val
 275 280 285

Pro Gly Phe Leu Gln Leu Gly Arg Glu Asp Gln Ile Ala Leu Leu Lys
 290 295 300

Ala Ser Thr Ile Glu Ile Met Leu Leu Glu Thr Ala Arg Arg Tyr Asn
 305 310 315 320

His Glu Thr Glu Cys Ile Thr Phe Leu Lys Asp Phe Thr Tyr Ser Lys
325 330 335

Asp Asp Phe His Arg Ala Gly Leu Gln Val Glu Phe Ile Asn Pro Ile
340 345 350

Phe Glu Phe Ser Arg Ala Met Arg Arg Leu Gly Leu Asp Asp Ala Glu
355 360 365

Tyr Ala Leu Leu Ile Ala Ile Asn Ile Phe Ser Ala Asp Arg Pro Asn
370 375 380

Val Gln Glu Pro Gly Arg Val Glu Ala Leu Gln Gln Pro Tyr Val Glu
385 390 395 400

Ala Leu Leu Ser Tyr Thr Arg Ile Lys Arg Pro Gln Asp Gln Leu Arg
405 410 415

Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr Leu Ser Ser
420 425 430

Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp Lys Lys Leu
435 440 445

Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu
450 455 460

<210> 6

<211> 1383

<212> DNA

<213> Homo sapiens

<400> 6

| | |
|--|-----|
| atgtcctctc ctaccacgag ttccctggat acccccctgc ctggaaatgg cccccctcag | 60 |
| cctggcgccc cttcttcttc acccaactgta aaggaggagg gtccggagcc gtggcccggg | 120 |
| ggtccggacc ctgatgtccc aggcactgat gaggccagct cagcctgcag cacagactgg | 180 |
| gtcatcccag atcccgaaga ggaaccagag cgcaagcgaa agaagggccc agccccgaag | 240 |
| atgctggggc acgagctttg ccgtgtctgt ggggacaagg cctccggctt cactacaac | 300 |
| gtgctcagct gcgaaggctg caagggcttc ttccggcgca gtgtggtccg tgggtggggc | 360 |
| aggcgctatg cctgccgggg tggcggaacc tgccagatgg acgctttcat gcggcgcaag | 420 |
| tgccagcagt gccggctgcg caagtgcaag gaggcaggga tgaggagca gtgcgtcctt | 480 |
| tctgaagaac agatccggaa gaagaagatt cggaacagc agcaggagtc acagtcacag | 540 |
| tcgcagtcac ctgtggggcc gcagggcagc agcagctcag cctctggggc tggggcttcc | 600 |

```

cctggtggat ctgaggcagg cagccagggc tccggggaag gcgaggggtgt ccagctaaca 660
gcggctcaag aactaatgat ccagcagttg gtggcggccc aactgcagtg caacaaacgc 720
tccttctccg accagcccaa agtcacgccc tggcccctgg gcgcagaccc ccagtcccg 780
gatgcccgcc agcaacgctt tgcccacttc acggagctgg ccatcatctc agtccaggag 840
atcgtggact tcgctaagca agtgccctgg ttcttcgagc tgggccggga ggaccagatc 900
gccctcctga aggcattcac tatcgagatc atgtgtctag agacagccag gcgctacaac 960
cacgagacag agtgtatcac cttcttgaag gacttcacct acagcaagga cgacttcac 1020
cgtgcaggcc tgcagggtga gttcatcaac cccatcttcg agttctcgcg ggccatgcgg 1080
cggctgggccc tggacgacgc tgagtacgcc ctgctcatcg ccatcaacat cttctcggcc 1140
gaccggccca acgtgcagga gccggggccgc gtggaggcgt tgcagcagcc ctacgtggag 1200
gcgtgtctgt cctacacgcg catcaagagg ccgcaggacc agctgcgctt cccgcgcatg 1260
ctcatgaagc tgggtgagcct gcgcacgctg agctctgtgc actcggagca ggtcttcgcc 1320
ttcggtctcc aggacaagaa gctgccgect ctgctgtcgg agatctggga cgtccacgag 1380
tga 1383

```

```

<210> 7
<211> 49
<212> DNA
<213> Homo sapiens

```

```

<400> 7
ggggacaagt ttgtacaaaa aagcaggctc gcttcgcaaa tgccgtcag 49

```

```

<210> 8
<211> 447
<212> PRT
<213> Homo sapiens
<400> 8

```

```

Met Ser Leu Trp Leu Gly Ala Pro Val Pro Asp Ile Pro Pro Asp Ser
1           5           10           15

```

```

Ala Val Glu Leu Trp Lys Pro Gly Ala Gln Asp Ala Ser Ser Gln Ala
20           25           30

```

```

Gln Gly Gly Ser Ser Cys Ile Leu Arg Glu Glu Ala Arg Met Pro His
35           40           45

```

```

Ser Ala Gly Gly Thr Ala Gly Val Gly Leu Glu Ala Ala Glu Pro Thr
50           55           60

```

```

Ala Leu Leu Thr Arg Ala Glu Pro Pro Ser Glu Pro Thr Glu Ile Arg
65           70           75           80

```

Pro Gln Lys Arg Lys Lys Gly Pro Ala Pro Lys Met Leu Gly Asn Glu
 85 90 95

Leu Cys Ser Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Asn Val
 100 105 110

Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Val Ile Lys
 115 120 125

Gly Ala His Tyr Ile Cys His Ser Gly Gly His Cys Pro Met Asp Thr
 130 135 140

Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Arg Lys Cys Arg Gln
 145 150 155 160

Ala Gly Met Arg Glu Glu Cys Val Leu Ser Glu Glu Gln Ile Arg Leu
 165 170 175

Lys Lys Leu Lys Arg Gln Glu Glu Glu Gln Ala His Ala Thr Ser Leu
 180 185 190

Pro Pro Arg Arg Ser Ser Pro Pro Gln Ile Leu Pro Gln Leu Ser Pro
 195 200 205

Glu Gln Leu Gly Met Ile Glu Lys Leu Val Ala Ala Gln Gln Gln Cys
 210 215 220

Asn Arg Arg Ser Phe Ser Asp Arg Leu Arg Val Thr Pro Trp Pro Met
 225 230 235 240

Ala Pro Asp Pro His Ser Arg Glu Ala Arg Gln Gln Arg Phe Ala His
 245 250 255

Phe Thr Glu Leu Ala Ile Val Ser Val Gln Glu Ile Val Asp Phe Ala
 260 265 270

Lys Gln Leu Pro Gly Phe Leu Gln Leu Ser Arg Glu Asp Gln Ile Ala
 275 280 285

Leu Leu Lys Thr Ser Ala Ile Glu Val Met Leu Leu Glu Thr Ser Arg
 290 295 300

Arg Tyr Asn Pro Gly Ser Glu Ser Ile Thr Phe Leu Lys Asp Phe Ser
 305 310 315 320

Tyr Asn Arg Glu Asp Phe Ala Lys Ala Gly Leu Gln Val Glu Phe Ile
 325 330 335

Asn Pro Ile Phe Glu Phe Ser Arg Ala Met Asn Glu Leu Gln Leu Asn
340 345 350

Asp Ala Glu Phe Ala Leu Leu Ile Ala Ile Ser Ile Phe Ser Ala Asp
355 360 365

Arg Pro Asn Val Gln Asp Gln Leu Gln Val Glu Arg Leu Gln His Thr
370 375 380

Tyr Val Glu Ala Leu His Ala Tyr Val Ser Ile His His Pro His Asp
385 390 395 400

Arg Leu Met Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr
405 410 415

Leu Ser Ser Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp
420 425 430

Lys Lys Leu Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu
435 440 445

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/07067

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/517 C07D239/95 C07D401/12 C07D403/04 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------------|
| X | WO 02 062798 A (REDDY RESEARCH FOUNDATION) 15 August 2002 (2002-08-15) claim 1 page 106, line 22 - page 107, line 6 page 1, line 17 - page 2, line 16 ----- | 1,13-33 |
| X | WO 97 20823 A (CRISCIONE LEOLUCA ;YAMAGUCHI YASUCHIKA (CH); CIBA GEIGY AG (CH); M) 12 June 1997 (1997-06-12) page 74; example 38 page 1, paragraph 1 ----- | 1,13,18, 22,30, 32,35 |
| X | WO 02 48152 A (BAKTHAVATCHALAM RAJAGOPAL ;BRIELMANN HARRY L (US); ELLIOTT RICHARD) 20 June 2002 (2002-06-20) page 59; example 12 page 6, paragraph 17 ----- | 1,13,18, 22,30, 32,35 |
| | -/- | |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

22 September 2003

Date of mailing of the international search report

06/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Kollmannsberger, M.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/07067

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | <p>COLLINS, J. L. ET AL.: "Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, 2002, pages 1963-1966, XP002225147</p> <p>cited in the application</p> <p>the whole document</p> | 1-33 |
| X | <p>GUPTA C M ET AL: "Drugs acting on the central nervous system. Syntheses of substituted quinazolones and quinazolines and triazepino- and triazocinoquinazolones"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 11, no. 2, 26 February 1968 (1968-02-26), pages 392-395, XP002156695</p> <p>ISSN: 0022-2623</p> <p>examples 13-16, 22, 23, 38; table 2</p> | 1, 4, 8, 13 |
| X | <p>MANABU HORI ET AL: "Novel 4-Substituted 2-Piperazinylquinazolines as potent Anticonvulsive and Antihypoxic Agents"</p> <p>CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 38, no. 5, 1990, pages 1286-1291, XP002128282</p> <p>ISSN: 0009-2363</p> <p>examples 3A-3H; table II</p> | 1 |
| X | <p>US 3 609 152 A (HESS HANS-JURGEN E ET AL)</p> <p>28 September 1971 (1971-09-28)</p> <p>examples III-X</p> | 1, 4, 8, 13 |
| X | <p>DATABASE CHEMCATS</p> <p>CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2001, XP002225148</p> <p>Order Number: TRG10400#07364-D;</p> <p>TRG10400#01891-D; TRG10400#01815-D;</p> <p>TRG10400#01814-D; TRG10400#01812-D;</p> <p>TRG10400#01811-D; TRG10400#01809-D;</p> <p>TRG10400#01736-D; TRG10400#01735-D;</p> <p>TRG10400#01732-D;</p> <p>TRG10400#01729-D</p> <p>& "Chem.Folio"</p> <p>15 January 2001 (2001-01-15), LION BIOSCIENCE AG, HEIDELBERG, GERMANY</p> | 1-3, 9 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/07067

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 14-25, 34, 35 are directed to a method of treatment of the human/animal body. Insofar as the claims could be searched, the search has been carried out based on the alleged effects of the compounds.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: -

Claims 1-12 encompass a large number of known compounds. The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). Additionally, support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, for only a very small proportion of the compounds and methods claimed. For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search is only complete for:

Compounds according to claims 1-10 which are mentioned in the prior art to have useful properties in the treatment of the diseases mentioned in claims 29-32; compounds as such according to claims 4-10.

Only some documents relevant to other subject-matter of the claims have been cited for illustration.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/07067

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 02062798 | A | 15-08-2002 | WO 02062798 A2 | 15-08-2002 |
| | | | WO 02062799 A1 | 15-08-2002 |
| | | | US 2002169175 A1 | 14-11-2002 |
| WO 9720823 | A | 12-06-1997 | AU 7692996 A | 27-06-1997 |
| | | | WO 9720823 A2 | 12-06-1997 |
| | | | ZA 9610020 A | 01-06-1997 |
| WO 0248152 | A | 20-06-2002 | AU 2027602 A | 24-06-2002 |
| | | | WO 0248152 A2 | 20-06-2002 |
| | | | US 2003036652 A1 | 20-02-2003 |
| US 3609152 | A | 28-09-1971 | BE 678216 A | 22-09-1966 |
| | | | DE 1620127 A1 | 12-03-1970 |
| | | | FR 5267 M | 31-07-1967 |
| | | | GB 1062357 A | 22-03-1967 |
| | | | GB 1174272 A | 17-12-1969 |
| | | | GB 1174273 A | 17-12-1969 |